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SUMMARY 
Background: Bariatric and metabolic surgery is an accepted treatment for 
obese patients with type 2 diabetes (T2D). However, the potential of 
gastrointestinal surgery regarding glycemic control in non-severely obese 
diabetic patients has yet to be defined. Along with weight loss itself, changes in 
gut hormone profiles after surgery play an important role in diabetes remission. 
Pathophysiology of T2D includes insulin resistance and insufficient insulin 
secretion, possibly modified by surgical procedures. Excessive or inadequate 
glucagon secretion promoting hepatic gluconeogenesis and glycogenolysis is 
also believed to contribute to hyperglycemia in diabetic patients. In the present 
experimental study, we explored the effect of established bariatric procedures, 
with and without duodenal exclusion, on glycemic control and pancreatic and 
gut hormone profile in Goto-Kakizaki (GK) rats, a lean animal model of T2D. 
Data obtained from our experimental model were supplemented by the results 
of a clinical study on the effects of sleeve gastrectomy (SG) on impaired fasting 
glucose (IFG) and T2D in obese patients. 
Methods: Forty 12- to 14-week-old GK rats were randomly assigned to four 
groups: control group (GKC), sham surgery (GKSS), sleeve gastrectomy 
(GKSG), and gastric bypass (GKGB). Ten age-matched Wistar rats served as a 
non-diabetic control group (WIC). Glycemic control and plasma lipids were 
assessed at the beginning of the observation period and four weeks after 
surgery. Fasting and mixed meal-induced plasma levels of insulin, glucagon, 
ghrelin, glucagon-like peptide-1 (GLP-1), and peptide tyrosine tyrosine (PYY) 
were measured. In the clinical study, SG as stand-alone treatment for severe or 
morbid obesity was performed in 23 patients with T2D or IFG. No post-operative 
complications occurred and patients were dismissed from hospital on day 2 
after surgery. Body mass index (BMI), fasting plasma glucose (FPG) and fasting 
insulin were determined before and up to 24 months after surgery. Insulin 
resistance and beta-cell function were calculated using the modified 
homeostasis model assessment (HOMA2).   
Results: Glycemic control was improved in GKSG and GKGB groups. Fasting 
insulin and glucagon levels in WIC rats were similar to GKC or GKSS. Fasting 
glucagon levels were highest in GKGB. No significant meal-induced variations 
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of glucagon levels were observed in WIC, GKC or GKSS rats, whereas in 
groups GKSG and GKGB a significant rise occurred 30 minutes after a mixed 
meal, maintained up to 60 minutes. Both GKSG and GKGB rats showed an 
elevated glucagon-insulin ratio at 60 minutes in comparison to all other groups. 
Mixed meal-induced gut hormone profiles in WIC rats were significantly different 
from GKC and GKSS. After SG and gastric bypass (GB), GK rats showed a 
similar postprandial decrease in ghrelin as observed in non-diabetic WIC rats. 
Following both surgical procedures, a significant meal-induced increase in PYY 
and GLP-1 could be demonstrated. In the clinical study, BMI, FPG and fasting 
insulin improved significantly as early as 3 months after surgery. A three-fold 
increase in pre-operative insulin resistance (3.05) decreased to near-normal 
values (1.14) during the same period. Interestingly, overall beta-cell function 
diminished at 12 months of follow-up (79.6%), in comparison to pre-operative 
values (117.8%). Patients with a markedly reduced preoperative beta-cell 
function (<40%) did not achieve a complete remission after surgery. 
Conclusions: SG and GB induced a similar improvement in overall glycemic 
control in lean diabetic rodents. GKC and GKSS rats showed similar glucagon 
levels in comparison to non-diabetic WIC rats, without variation after a mixed 
meal. GKSG or GKGB groups improved their overall glucose metabolism, albeit 
an augmented post-procedural glucagon secretion. Meal-induced profiles of 
ghrelin, GLP-1, and PYY in GK rats were significantly modified by SG and GB 
and became similar to non-diabetic Wistar rats. In obese patients with T2D or 
IFG, commonly characterized by an increased insulin resistance and insulin 
secretion, SG induced remission through reduction of insulin resistance. Our 
data does not support the hypothesis that duodenal exclusion and early contact 
of food with the ileal mucosa alone may explain changes in gut hormone profile 
in GK rats after gastrointestinal surgery. In our experimental study, an 
augmented glucagon secretion after surgery did not contribute to an impaired 
glucose tolerance. Pre-operative insulin resistance and beta-cell function 
calculated by mathematical models like HOMA2 might have prognostic value 
and should be studied in patients undergoing metabolic surgery. 
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RESUMO 
Introdução: A cirurgia bariátrica e metabólica representa uma opção 
terapêutica válida em doentes obesos com diabetes tipo 2 (T2D). No entanto, o 
seu potencial no controlo glicémico em doentes sem obesidade severa ou 
mórbida não está, ainda, completamente esclarecido. Para além da perda de 
peso, as alterações no perfil de hormonas digestivas têm um papel importante 
na remissão da T2D. A patofisiologia da T2D é caracterizada pela resistência 
hepática e periférica à insulina e a deficiente secreção de insulina, sendo 
possível a sua modulação através de intervenções cirúrgicas gastrointestinais. 
Um fator que ainda pode contribuir para a hiperglicémia em doentes diabéticos 
consiste no aumento da glicogenólise e gluconeogénese hepáticas devido à 
secreção excessiva ou inadequada de glucagina. No presente estudo 
experimental avaliámos o efeito de técnicas cirúrgicas estabelecidas no 
tratamento da obesidade, com ou sem exclusão duodenal, no controlo 
glicémico e perfil hormonal intestinal e pancreático em ratos Goto-Kakizaki 
(GK), um modelo animal não obeso da T2D. Os resultados do estudo animal 
foram complementados por um estudo clínico que avaliou os efeitos da 
gastrectomia vertical calibrada na alteração da glicémia do jejum (IFG) e na 
T2D em doentes obesos. 
Métodos: Quarenta ratos GK, com 12 – 14 semanas de idade, foram 
distribuídos de forma randomizada por 4 grupos: grupo controlo (GKC), cirurgia 
simulada (GKSS), gastrectomia vertical (GKSG), e bypass gástrico (GKGB). 
Dez ratos Wistar da mesma idade formaram o grupo controlo não-diabético 
(WIC). O controlo glicémico e os lipídeos plasmáticos foram avaliados no início 
do período de observação e quatro semanas após a cirurgia. Determinaram-se 
os níveis plasmáticos, em jejum e após uma refeição líquida mista, de insulina, 
glucagina, grelina, peptídeo semelhante à glucagina-1 (GLP-1) e peptídeo 
tirosina tirosina (PYY). No estudo clínico, 23 doentes obesos, portadores de 
T2D ou IFG, foram submetidos a gastrectomia vertical (SG) calibrada por via 
laparoscópica; não houve complicações pós-operatórias e todos os doentes 
tiveram alta hospitalar no segundo dia após a intervenção cirúrgica. 
Determinaram-se o índice de massa corporal (BMI), a glicémia e a insulinémia 
em jejum antes e até 24 meses depois da operação. A resistência à insulina 
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(IR) e a função da célula beta foram calculados usando o modelo de avaliação 
da homeostase modificado (HOMA2).   
Resultados: O controlo glicémico melhorou nos grupos GKSG e GKGB. A 
insulinémia e a glucaginémia em jejum foram semelhantes nos grupos WIC e 
GKC ou GKSS. A glucaginémia foi mais elevada no grupo GKGB. Nos grupos 
WIC, GKC ou GKSS não se observaram alterações pós-prandiais significativas 
da glucagina. No entanto, ocorreram subidas significativas aos 30 minutos após 
a refeição líquida tanto no grupo GKSG como no GKGB, mantida até aos 60 
minutos. Os ratos dos grupos GKSG e GKGB apresentaram uma razão 
glucagina-insulina elevada aos 60 minutos, em comparação com todos os 
outros. Os perfis pós-prandiais das hormonas do tubo digestivo foram 
significativamente diferentes nos ratos Wistar quando comparados com os 
GKC e GKSS. Após SG e bypass gástrico (GB), os ratos GK apresentaram 
uma descida pós-prandial da grelina, semelhante aos WIC não diabéticos. 
Observaram-se ainda subidas pós-prandiais significativas do PYY e GLP-1 
após ambas as técnicas cirúrgicas.  
No estudo clínico, o BMI, a glicémia e a insulinémia em jejum melhoraram 
significativamente aos 3 meses do pós-operatório. A IR, aumentada até 300% 
no pré-operatório, desceu no mesmo período até valores próximos da 
normalidade (114%). Globalmente, a função da célula beta diminuiu aos 12 
meses de catamnese (79.6%), em comparação com os valores pré-operatórios 
(117.8%). Doentes com uma função reduzida da célula beta no pré-operatório 
(<40%) não obtiveram remissão completa após a intervenção cirúrgica. 
Conclusão: Em roedores diabéticos não obesos, a SG e o GB permitiram uma 
melhoria semelhante no controlo glicémico global. Os ratos dos grupos GKC e 
GKSS apresentaram níveis semelhantes de glucagina quando comparados a 
ratos Wistar não diabéticos; estes valores não se modificaram após uma 
refeição mista. Os grupos GKSG e GKGB melhoraram o controlo global da 
glicémia, apesar de uma secreção aumentada de glucagina. Os perfis pós-
prandiais de grelina, GLP-1 e PYY nos ratos GK foram significativamente 
diferentes após SG e GB tornando-se semelhantes aos dos ratos Wistar não-
diabéticos. Em doentes obesos com T2D ou IFG, geralmente caracterizados 
por um incremento da secreção de insulina e da IR, a SG induziu a remissão 
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através de uma diminuição da IR. Os nossos resultados não sustentam a teoria 
que a exclusão duodenal e o contacto precoce de alimentos com a mucosa 
ileal explicam, por si só, as alterações do perfil das hormonas digestivas em 
ratos GK após cirurgia gastrintestinal. No estudo experimental, o aumento pós-
operatório dos níveis plasmáticos de glucagina não contribuiu para a 
diminuição da tolerância à glicose. A IR e a função da célula beta pré-
operatórias, calculadas através de modelos matemáticos como a HOMA2, 
podem ter valor prognóstico e devem ser avaliadas em doentes submetidos a 
cirurgia metabólica.  
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PRELIMINARY NOTE 
The initial conception of our research project was laid out in 2007 and accepted 
as project for a doctoral thesis by the Faculty of Medicine of the University of 
Coimbra (FMUC) in 2008. Due to unforeseen difficulties regarding the 
reproduction of the local breeding colony of Goto-Kakizaki (GK) rats belonging 
to the Institute of Physiology of FMUC, in the context of relocation from the 
Center for Experimental Research at the University Hospital of Coimbra to new 
facilities at the Institute for Biomedical Imaging and Life Sciences (IBILI), 
preliminary experimental studies began in late 2010. Since then, a considerable 
amount of research on the subject of gut hormones and enteroendocrine effects 
of surgery has been published. For practical reasons and to increase the 
scientific substance, all relevant content of papers published to date of final 
outline of our thesis (July 2014) will be reflected in the corresponding sections 
of the manuscript, including the section on “BACKGROUND AND CURRENT 
STATE OF RESEARCH”. 
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INTRODUCTION 
According to recent data, 382 million people suffer from diabetes worldwide, 
many of them undiagnosed. Type 2 diabetes accounts for most cases and, 
besides genetic predisposition, sedentary lifestyle, overweight, and poor dietary 
habits represent main contributing factors. Until 2035, a 55% increase in 
prevalence is expected (International Diabetes Federation, 2013). Diabetes 
imposes a major burden on health costs and leads to premature death due to 
complications like cardiovascular disease and diabetic nephropathy with 
subsequent renal insufficiency. Other non-lethal consequences of diabetes 
include debilitating retinopathy and blindness or peripheral neuro-vascular 
disease and amputation.  
Conservative measures including behavioral weight loss programs and 
intensive life-style interventions have a favorable short-term effect on body 
weight and glycemic control in obese patients with type 2 diabetes if compared 
to standard care (Unick et al., 2011) and also improve glucose-stimulated 
insulin secretion and beta-cell function associated with augmented incretin 
secretion (Solomon et al., 2010). However, the long-term results of the Look 
AHEAD (Action for Health in Diabetes) trial turned out to be rather disappointing 
with only half of the patients obtaining a weight-loss over 5% of initial body 
weight, after 8 years of follow-up (The Look AHEAD Research Group, 2014); 
impact on diabetes control and glycated hemoglobin levels was reduced (Unick 
et al., 2013). Regarding the primary endpoint of the study, cardiovascular 
morbidity and mortality was similar in both groups (intensive lifestyle 
intervention or usual diabetes support and education) and the trial was 
interrupted after a mean follow-up of 9.6 years and 5,145 enrolled patients  (The 
Look AHEAD Research Group, 2014). 
Surgical treatment of obesity has been shown to be more effective than medical 
treatment, not only regarding weight loss, but also concerning control of 
comorbidities like type 2 diabetes (T2D). The Swedish Obese Subjects (SOS) 
study enrolled prospectively 2,010 patients submitted to bariatric surgery and 
2,037 contemporaneously matched controls treated conservatively. After 10 
years of follow-up, the incidence of diabetes was 7% in the surgical group and 
24% in the group submitted to conservative treatment (p<0.001). Recovery from 
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pre-existing diabetes was more frequent in the surgical group (36% vs. 13%), 
underscoring the favorable effects of bariatric surgery on diabetes control 
(Sjöström et al., 2004). Overall mortality during a follow-up period up to 15 
years was lower in the surgical group with an adjusted cumulative hazard ratio 
of 0.71 (Sjöström et al., 2007).  
In specialized centers, the beneficial effect of bariatric surgery, particularly 
gastric bypass (GB), on glycemic control in obese patients with T2D or impaired 
fasting glucose (IFG) has been recognized for decades (Pories et al., 1995, 
1987). Remission was observed in nearly all patients with impaired fasting 
glucose (97.8%) and in most patients with T2D (82.9%). Similar or even better 
results regarding diabetes control were obtained after bilio-pancreatic diversion 
(BPD) with remission rates close to 100% (Marinari et al., 2006; Scopinaro, 
2006; Scopinaro et al., 1998).  
An extensive and systematic meta-analysis including thousands of patients 
confirmed the effect of bariatric surgery on weight loss and glycemic control 
(Buchwald et al., 2004). Addressing specifically the question of diabetes 
remission after bariatric surgery, a more recent meta-analysis concluded that a 
complete resolution of the clinical manifestations of diabetes, e. g. fasting 
glycemia <100 mg/dl and glycated hemoglobin (HbA1c) <6% without 
medication, occurred in 78.1% of patients (Buchwald et al., 2009). Diabetes was 
improved or resolved in 86.6% and remission was maintained for more than 2 
years in 74.6%. BPD revealed to be the most effective surgical technique 
(95.1% resolved), followed by GB (80.3% resolved), vertical banded 
gastroplasty (79.7% resolved), and laparoscopic adjustable gastric banding 
(56.7% resolved).  
In many patients, improvement of glycemic control occurs rather early after GB, 
within hours or days, before any significant weight loss has been achieved 
(Pories et al., 1995; Smith et al., 1996) and was thought to be related to neuro-
endocrine mechanisms due to the bypass of the gastric antrum and duodenum. 
Analyzing their series of 608 patients submitted to GB in 2001, including 146 
diabetic patients and 152 with impaired glucose tolerance (IGT), Pories and 
Albrecht postulated the hypothesis that, in vulnerable individuals, T2D might be 
caused by an overstimulation of the foregut and pancreas by incretins like 
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glucagon-like peptide-1 (GLP-1) or glucose-dependent insulinotropic 
polypeptide (GIP) (Pories and Albrecht, 2001).  
More recently, superobese patients with T2D or IGT, submitted to sleeve 
gastrectomy (SG) as first stage of bilio-pancreatic diversion with duodenal 
switch (BPD-DS), were shown to ameliorate glucose control at 18 months of 
follow-up, without any bypass of the duodenum and without completing the 
second stage of surgery (Silecchia et al., 2006). In another study, including 33 
obese or superobese patients, diabetes remission rates after SG alone reached 
84.6% after 3 years and 76.9% after 5 years, but 9 patients were submitted to 
the second stage of BPD-DS and excluded from further analysis (Abbatini et al., 
2013).  
SG and GB represent distinct surgical techniques regarding the exclusion of the 
duodenum and proximal jejunum, hypothetically implied in diabetes remission 
(Pories and Albrecht, 2001). Interestingly, recent data suggests that both 
techniques are similarly effective in treating T2D in severely and morbidly obese 
patients, at least in the short term (Cutolo et al., 2012; de Gordejuela et al., 
2011; Jiménez et al., 2012; Keidar et al., 2013; Nocca et al., 2011; Zhang et al., 
2013). Notwithstanding, a meta-analysis including five randomized controlled 
trials on diabetes remission demonstrated that GB was more effective than SG 
at the cost of an increased complication rate, but many analyzed parameters 
were only available from 2 or 3 studies (Li et al., 2013). A more extensive 
review and meta-analysis including 33 studies and 1375 patients did not show 
any significant differences in short-term diabetes remission after both 
techniques (Yip et al., 2013). Furthermore, recent randomized controlled trials 
comparing medical and surgical treatment of T2D in obese patients 
demonstrated superior results after SG, GB, and BPD in comparison to medical 
treatment (Kashyap et al., 2013; Leslie et al., 2012; Mingrone et al., 2012; 
Palikhe et al., 2014; Samat et al., 2013; Schauer et al., 2012). 
Less is known regarding the efficacy of surgical approaches in controlling T2D 
in patients that are simply overweight (body mass index [BMI] 25 – 30 kg/m2) or 
suffer from mild obesity (BMI 30 – 35 kg/m2). In a small series from Italy, nine 
diabetic patients with a BMI of 28 – 35 kg/m2 were submitted to SG, with 
favorable results regarding diabetes control in comparison to a control group, 
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one year after surgery (Abbatini et al., 2012). Two studies from Chile including 
30 and 31 patients with mild obesity submitted to GB showed similar results 
with remission rates of 65% and 93.6%, after 2 and 3 years of follow-up (Boza 
et al., 2011a; Lanzarini et al., 2013). However, two studies from Brazil revealed 
conflicting results after GB. A less favorable outcome was observed in 27 
diabetic patients with class I obesity (BMI 30 – 35 kg/m2)  achieving remission 
only in 48.1% of cases after a mean follow-up of 20 months (de Sa et al., 2011). 
In another study in the same population, 88% of 66 patients achieved remission 
(HbA1c <6.5%) after a median follow-up of 5 years (R. V Cohen et al., 2012). In 
diabetic Asian patients with a BMI <35 Kg/m2, remission rates after GB were 
merely about 55% (fasting plasma glucose (FPG) <110 mg/dl and HbA1c <6%), 
even with a markedly improved insulin resistance, after a follow-up of 2 years 
(Lee et al., 2011b). Similar results were obtained in Indian patients with class I 
obesity and, after 5 years of follow-up, diabetes remission according to ASA 
criteria was maintained in 57.7% of patients (Lakdawala et al., 2013). BPD in 30 
diabetic patients with mild obesity or simply overweight showed slightly better 
results and diabetes remission (defined as HbA1c <6%) was obtained in 67% 
(Scopinaro et al., 2011). 
Diabetes resolution after bariatric surgery is associated with reduction in hepatic 
and peripheral insulin resistance after gastric banding, gastric bypass or sleeve 
gastrectomy (Ballantyne et al., 2006; Benaiges et al., 2013; Rizzello et al., 
2010; Wickremesekera et al., 2005). However, gut hormones and the 
enteroinsular axis play a renowned role in insulin secretion, and in obese 
patients neuroendocrine mechanisms controlling hunger and satiety seem to be 
affected by bariatric surgical procedures (le Roux et al., 2006). Nonetheless, the 
effect of gastrointestinal surgery on type 2 diabetes in non-severely or morbidly 
obese patients and underlying changes in gut hormone profiles remains to be 
further elucidated.  
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BACKGROUND AND CURRENT STATE OF RESEARCH 
Short overview on the pathophysiology of type 2 diabetes 
Criteria for the diagnosis of diabetes include HbA1c levels ≥6.5%, FPG ≥126 
mg/dL, 2-h plasma glucose (PG) after an 75g oral glucose tolerance test 
≥200mg/dL, or random PG ≥200mg/dL in a subject with clinical manifestations 
of hyperglycemia (American Diabetes Association, 2014). Individuals with IFG 
(FPG levels 100 -125 mg/dL) or IGT (2-h PG levels 140 – 199 mg/dL) are 
considered at an increased risk for the development of diabetes.  
Whereas type 1 diabetes is characterized by an absolute insulin deficiency due 
to progressive beta-cell destruction, patients with T2D present with an 
insufficient pancreatic insulin secretion in response to a given plasma glucose 
level to maintain normoglycemia in the presence of hepatic and peripheral 
insulin resistance (DeFronzo, 1992). Insulin resistance represents a key feature 
of T2D and is associated with accumulation of hepatic fat deposits (Seppälä-
Lindroos et al., 2002), reduced suppression of serum free fatty acids (FFA) by 
insulin, and intramyocellular triglyceride content in the skeletal muscle (Guo, 
2007). In obese patients, pro-inflammatory cytokine expression and 
suppression of anti-inflammatory proteins like adiponectin ads to insulin 
resistance and nonalcoholic fatty liver disease (NAFLD) (Asrih and Jornayvaz, 
2013). Progression of the condition leads to beta-cell failure, frequently referred 
to as exhaustion of the beta-cell, and mechanisms like glucotoxicity, lipotoxicity 
and islet amyloid polypeptide (IAPP) deposition have been implicated in 
deterioration of insulin secretion (DeFronzo, 2009). 
Loss of the incretin effect due to changes in incretin levels and action like 
resistance to GIP or reduced secretion of GLP-1 plays an additional role in the 
development of type 2 diabetes (Holst et al., 2009). Furthermore, the beneficial 
effect of both hormones on beta-cell proliferation and neogenesis, as well as the 
prevention of apoptosis, seems to be impaired in diabetic patients. Excessive or 
inadequate secretion of glucagon from pancreatic alpha-cells promoting hepatic 
gluconeogenesis and glycogenolysis possibly also contributes to impaired 
glucose tolerance in type 2 diabetes (Gastaldelli et al., 2000; Jiang and Zhang, 
2003).  
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Endocrine function of the gut 
Gut hormones from enteroendocrine cells of the gastrointestinal mucosa play 
an important role in the regulation of energy homeostasis and glucose 
metabolism. Besides acting on the regulation of satiety and hunger via 
neuroendocrine pathways, gut-derived peptide hormones control gastric 
emptying and stimulate post-prandial insulin release from pancreatic beta-cells 
(Bloom et al., 2005; Drucker, 2007).  
The increased oral glucose tolerance in comparison to intravenous 
administration has been described since the late 19th century (Creutzfeldt, 
1979). However, only the availability of a radioimmunoassay for insulin 
determination in the 1960’s allowed to demonstrate an intensified insulin 
response after an oral glucose load in comparison to intravenous administration 
(Dupre, 1964; McIntyre et al., 1964). The insulinotropic effect of a peptide with a 
“glucagon-like immunoreactivity” stimulated by oral glucose intake was 
described (Samols et al., 1966, 1965), eventually derived from the gut as it was 
still present in patients submitted to pancreatectomy (Samols and Marks, 1967).  
Gastric inhibitory peptide (GIP)1 was isolated in 1970 (Brown et al., 1970) and 
its origin from the duodenal K-cells was demonstrated (Buffa et al., 1975; Polak 
et al., 1973). In both rats (Turner et al., 1973) and humans (Dupre et al., 1973), 
it stimulated insulin secretion, but administration of exogenous GIP would 
stimulate glucagon secretion as well (Taminato et al., 1977), apparently in a 
dose-dependent fashion at basal glucose concentrations (J. J. Meier et al., 
2003). In obese patients, fat together with glucose stimulated the release of 
immunoreactive GIP more than glucose alone, and even more so in subjects 
with impaired glucose tolerance that also presented with elevated fasting levels 
of GIP (Creutzfeldt et al., 1978). Apparently, in patients with T2D, GIP would not 
increment insulin release as it would in non-diabetic subjects (Elahi et al., 
1994), having a defective receptor in patients with T2D being proposed to 
explain the reduced insulinotropic effect in these patients (Holst et al., 1997). 
However, whereas the continuous infusion of GIP in diabetic patients would 
only produce a weak response regarding insulin secretion, the response to a 
                                                             
1
 Later denominated “glucose-dependent insulinotropic polypeptide” due to its effects on insulin 
secretion. 
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bolus administration of GIP seems to remain preserved, making a defective 
receptor unlikely (Meier et al., 2004). 
In 1981, a clinical study was published that showed a post-prandial elevation of 
enteroglugacon from the distal gut in obese patients that had undergone jejuno-
ileal or biliopancreatic bypass (Sarson et al., 1981). It could be demonstrated in 
extracts from rat gut that, after neutralization and immune-absorption of GIP, 
more than 50% of the incretin effect remained, indicating the presence of 
additional gut hormones that stimulate insulin secretion (Ebert et al., 1983). 
Further studies determined the potent insulinotropic effect of the 31 amino acids 
containing form of GLP-1 in rats (Mojsov et al., 1987) and man (Kreymann et 
al., 1987). GLP-1 is found in intestinal L-cells with an increasing concentration 
in the distal jejunum, ileum and colon (Eissele et al., 1992) and was recognized 
as a new incretin hormone with distinguished properties (Orskov, 1992).  
A marked elevation of GLP-1 was shown 20 years after jejuno-ileal bypass 
(Näslund et al., 1998), confirming the findings of the earlier study published in 
1981 by Sarson et al. Besides effects on glucose homeostasis, GLP-1 inhibits 
gastric acid secretion (O’Halloran et al., 1990) and gastric emptying (Nauck et 
al., 1997). It also acts on the central nervous system in specific areas of the 
hypothalamus by inhibiting food intake and mediating satiety in rats (Turton et 
al., 1996) and humans (Gutzwiller et al., 1999b). In diabetic patients, it does not 
only decrease energy intake and enhance satiety, but also controls postprandial 
plasma glucose levels (Gutzwiller et al., 1999a). Furthermore, administration of 
GLP-1 to healthy volunteers reduced the postprandial increase in serum 
triglycerides, besides delaying gastric emptying as described before (Meier et 
al., 2006). In overweight and obese humans, meal-induced secretion of GLP-1 
was more pronounced after a meal with high fat content in comparison to high 
content in carbohydrates and associated with short-term control of food intake 
(Gibbons et al., 2013). Additionally, GLP-1 modulates plasma ghrelin in the 
postprandial period preventing an immediate decrease in ghrelin levels after the 
meal and suppressing the subsequent increase in the late postprandial period 
(Hagemann et al., 2007). In an animal model, enhanced protein-mediated GLP-
1 secretion after duodenal administration of zein hydrolysate was inhibited 
through vagal denervation, whereas the effect of jejunal and ileal administration 
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was maintained, highlighting the different mechanisms of GLP-1 secretion 
throughout the gastrointestinal tract (Hira et al., 2009).  
Peptide tyrosine tyrosine (PYY) was initially isolated from porcine upper small 
intestine (Tatemoto and Mutt, 1980) and an inhibitory effect on exocrine 
pancreatic secretion was described in cats (Tatemoto, 1982). The molecular 
structure of PYY is similar to neuropeptide Y (Tatemoto et al., 1982) and further 
studies identified PYY in L-cells of the distal small bowel and, in increasing 
concentrations, in the colon and rectum (Adrian et al., 1985; Lundberg et al., 
1982). PYY is secreted in response to food intake, particularly with a high lipid 
content (Adrian et al., 1985). In the central nervous system, subtype PYY3-36 
interacts as an agonist with the Y2 receptor (Y2R) on neuropeptide Y (NPY) 
neurons in the arcuate nucleus of the hypothalamus inhibiting food intake 
(Batterham et al., 2002). In humans, functional magnetic resonance imaging 
could demonstrate activation of specific brain areas after exogenous 
administration of PYY3-36 and GLP-17-36, similar to those observed after regular 
food intake (Batterham et al., 2007; De Silva et al., 2011). Recent research in 
mice suggested that PPY acts also on GLP-1 secretion through activation of 
peripheral Y2R (Chandarana et al., 2013). 
Besides release from intestinal L-cells, PYY is also co-stored with glucagon in 
pancreatic alpha-cells. In vivo experiments in a mouse model showed no effect 
on basal plasma levels of insulin or glucagon, but stimulated secretion of both 
hormones was inhibited (Böttcher et al., 1989). PYY restrains the glucose-
stimulated insulinotropic action of GIP in dogs (Guo et al., 1989), but 
insulinostatic effects of PYY on glucose-stimulated insulin secretion through 
inhibition of the cyclic AMP cascade were also observed in isolated mouse 
islets (Nieuwenhuizen et al., 1994). Hence, a combined effect of direct intra-islet 
action of PYY and indirect processes mediated through other gut hormones is 
plausible.  
Similar to PYY, oxyntomodulin (OXM) is another enterohormone derived from 
proglucagon and secreted from L-cells in the distal ileum (Bataille et al., 1981). 
Actions of OXM include inhibition of basal and postprandial gastric acid 
secretion, gastroduodenal motility and gastric emptying (Schjoldager et al., 
1989). Furthermore, OXM reduces food intake in rats (Dakin et al., 2001) and 
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humans (Cohen et al., 2003). In obese non-diabetic volunteers, preprandial 
subcutaneous administration of OXM resulted in significant weight loss over a 
four-week study period (Wynne et al., 2005). A cumulative effect on food intake 
during the simultaneous administration of PPY has been demonstrated (Field et 
al., 2010). Besides a decrease in energy intake, OXM promoted an increase in 
activity related energy expenditure in a small randomized controlled trial 
including 15 healthy overweight and obese volunteers (Wynne et al., 2006). 
Recent research suggested that dual activation of the GLP-1 receptor and the 
glucagon receptor by OXM is involved in weight loss and maintenance of 
glucose homeostasis after extrinsic administration in mice (Du et al., 2012; 
Kosinski et al., 2012; Pocai, 2014). 
In the late 1990s, a new gastrointestinal hormone was identified (Kojima et al., 
1999) that binded to the previously described orphan growth hormone 
secretagogue receptor (GHS-R) in the pituitary gland and the hypothalamus 
(Howard et al., 1996). Ghrelin, an acylated peptide of 28 amino acids, 
represents a growth-hormone secretagogue and is secreted mainly from the 
gastric fundus and, to a far lesser extent, throughout the remaining 
gastrointestinal tract (Date et al., 2000; Kojima et al., 1999). Its exogenous 
administration induces an increase in food intake and adiposity in rats through 
activation of the growth hormone receptor on NPY neurons in the arcuate 
nucleus of hypothalamus (Tschöp et al., 2000; Wren et al., 2000). Alongside 
with effects on the central regulation of satiety and hunger, ghrelin acts 
indirectly on gastric acid secretion via stimulation of the vagus nerve (Date et 
al., 2001). In analogy to observations in rodents, intravenous ghrelin infusion 
increases food intake in man (Wren et al., 2001). Generally, plasma ghrelin is 
decreased in obese patients if compared to lean controls (Tschöp et al., 2001), 
particularly in patients with insulin resistance (McLaughlin et al., 2004). 
Somewhat conversely, obese patients with NAFLD, a condition associated with 
hepatic insulin resistance, exibit higher ghrelin levels together with more 
advanced fibrosis and steatohepatitis (Estep et al., 2011). 
Initial studies in rats showed an upregulation of ghrelin secretion in the fasting 
state and after insulin administration (Toshinai et al., 2001) indicating a working 
feedback mechanism for the stimulation of food intake. However, contradicting 
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research in the isolated rat stomach found that insulin and amino acids 
decreased ghrelin secretion, whereas lipids had no effect and acetylcholine 
increased secretion significantly (Shrestha et al., 2009). In healthy human 
volunteers a similar inhibition of ghrelin secretion after insulin-induced 
hypoglycemia was demonstrated (Broglio et al., 2004a; Leonetti et al., 2004). 
Apparently, ghrelin has an effect on glucose metabolism inducing 
hyperglycemia and a decrease in serum insulin levels in healthy lean volunteers 
(Broglio et al., 2001). The particular importance of ghrelin in maintaining 
glucose homeostasis is supported by the discovery of the islet ghrelin cell 
(Wierup et al., 2002) and reinforced by the description of GHS-R expression in 
pancreatic beta-cells (Dezaki et al., 2008). Besides stimulation of GHS-R by 
circulating ghrelin, a paracrine effect on insulin secretion was proposed, 
apparently in a dose-dependent fashion. In isolated mouse islets, ghrelin in very 
high concentrations increased glucose-stimulated insulin release, whereas low 
concentrations inhibited insulin secretion (Salehi et al., 2004). However, most 
studies report an inhibitory effect of ghrelin on insulin release that, in a 
physiological context, acts in a reciprocal association with insulin (Dezaki et al., 
2008; Peng et al., 2012; Tong et al., 2010; Wierup et al., 2014). Thus, high 
fasting plasma ghrelin levels are linked to low fasting insulin levels and the post-
prandial increase in insulin secretion is accompanied by a decrease in 
circulating ghrelin. Apparently, inhibitory effects on insulin secretion are 
additionally mediated by suppression of GLP-1-induced insulin release by 
exogenous and endogenous islet-derived ghrelin (Damdindorj et al., 2012). 
Less attention has been paid to the enteroendocrine function of cholecystokinin 
(CCK), a gastrointestinal peptide secreted from duodenal and jejunal I-cells. Its 
anorectic effects are mediated through receptors on the vagus nerve and 
activation of specific areas in the brain stem and hypothalamus. Apparently, 
long-term weight control is independent from the CCK1 and CCK2 receptor as 
receptor-deficient mice showed a comparable daily food intake, weight gain and 
glucose homeostasis in comparison to wild-type animals. Yet, exogenous 
administration of CCK would reduce food intake in wild-type and CCK2 
receptor-deficient mice, thus indicating a role for the CCK1 receptor in the 
regulation of short-term satiety (Kopin et al., 1999). However, recent research 
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questions the role of the CCK2 receptor in long-regulation of hunger and satiety 
as receptor-deficient mice developed hyperphagia, obesity and impairment of 
glucose homeostasis (Clerc et al., 2007).  
The importance of CCK-mediated intra-duodenal fat hydrolysis on GLP-1 
secretion has been shown in healthy volunteers that received an intra-duodenal 
fat infusion with or without an irreversible inhibitor of gastro-intestinal lipases 
(orlistat). In conclusion, the selective blockade of the CCK1 receptor abolished 
the effect of fat hydrolysis on GLP-1 secretion (Beglinger et al., 2010). An 
analogous effect of CCK1 receptor blockage on the secretion of ghrelin and 
PPY had been previously observed using a similar study design (Degen et al., 
2007). 
 
Enteroendocrine effects of bariatric and metabolic surgery 
For many years, the effect of gastrointestinal surgery on body weight and 
comorbidities has been mainly attributed to restriction of caloric intake through 
reduction of gastric capacity or malabsorption due to bypassing of 
gastrointestinal segments. However, isolated early reports suggested that 
endocrine mechanisms associated with surgical procedures contribute to 
outcome after surgery and resolution of T2D (Ackerman, 1981; Halverson et al., 
1982; Pories et al., 1987; Sarson et al., 1981). Later on, the ascent of 
laparoscopic surgery, the epidemic-like spread of obesity, and the subsequent 
expansion of surgical treatment for obesity, together with the diffusion of 
knowledge on gut hormones, led to a significant increase in research on the 
enteroendocrine effects of gastrointestinal surgery for obesity and their 
contribution to outcome after treatment, particularly regarding diabetes 
remission. 
In general, the incretin effect of gastrointestinal hormones reflects the 
augmented insulin secretion after an oral glucose load in comparison to 
isoglycemic intravenous glucose administration defined by: [(InsulinAUCoral – 
InsulinAUCisoglycose IV) / InsulinAUCoral x 100%]
2. In obese diabetic patients, the 
incretin effect on insulin secretion is markedly impaired in comparison to obese 
                                                             
2
 AUC = area under the curve. 
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non-diabetic controls. Yet, one month after GB, a more than fourfold increase in 
the incretin effect was observed, alongside with amelioration of fasting blood 
glucose and a significantly augmented glucose-stimulated GLP-1 secretion. In 
comparison to the non-diabetic obese control group, the enhanced incretin 
effect in operated diabetic patients reached comparable values (Laferrère et al., 
2007) 
A postoperative decrease in fasting plasma GIP levels in obese diabetic 
patients was observed after GB and associated with normalization of blood 
glucose and fasting insulin, indicating a role for incretin metabolism in the 
amelioration of glucose homeostasis after duodenal exclusion (Rubino et al., 
2004). In non-diabetic obese patients, a similar reduction in fasting GIP levels 
occurred after GB, whereas fasting GLP-1 levels remained unchanged. In other 
studies, postprandial GLP-1 response increased significantly after GB in 
comparison to preoperative values (Borg et al., 2006) and lean or obese 
controls (le Roux et al., 2006). Effects of GB on GLP-1 secretion were 
maintained even 10 years after surgery (Dar et al., 2012). In obese patients with 
T2D, the impaired GLP-1 response to a standardized test meal was still 
significant in comparison to patients with normal or impaired glucose tolerance, 
six weeks after GB, but recovered after one year of follow-up (Morínigo et al., 
2006a). However, a peak plasma level of GLP-1 was observed 30 minutes after 
a mixed liquid meal, as early as 7 days after GB in obese diabetic patients, 
being more pronounced on subsequent observations at 30 and 90 days after 
surgery (Umeda et al., 2011). Analogous observations regarding glucose 
metabolism, plasma insulin and plasma GIP levels were described after BPD, 
as soon as one week after surgery. Fasting and glucose-stimulated GLP-1 
levels increased simultaneously (Guidone et al., 2006).  
Sleeve gastrectomy, a surgical technique without duodenal exclusion, produced 
similar results regarding GLP-1 secretion in comparison to patients submitted to 
GB (Nannipieri et al., 2013; Peterli et al., 2012, 2009; Romero et al., 2012). In 
another study in obese diabetic patients submitted to SG, the first phase of 
insulin secretion after an intravenous glucose tolerance test improved early after 
surgery and secretion of GLP-1 and PYY was increased. However, patients with 
longstanding T2D (>10 years) did not experience the same improvement in 
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glucose homeostasis and secretion of gut hormones (Basso et al., 2011). 
Interestingly, in Asian patients with a BMI of 31.5±3.2 kg/m2 and longstanding 
type 2 diabetes submitted to either SG or GB, a far superior rate of diabetes 
resolution was observed after GB in comparison to SG, albeit a similar 
decrease in BMI and enhancement of meal-induced GLP-1 secretion after both 
surgical procedures (Lee et al., 2011a).   
After GB in obese human patients, whether diabetic or not, a sharp and 
statistically significant postprandial rise of PYY could be observed if compared 
to lean or obese controls (Borg et al., 2006; Korner et al., 2006, 2005; le Roux 
et al., 2006; Morínigo et al., 2006b). Obese patients submitted to SG, together 
with partial enterectomy and omentectomy (Santoro et al., 2008, 2006), or SG 
alone (Basso et al., 2011; Dimitriadis et al., 2013; Karamanakos et al., 2008) 
experienced similar changes in PYY after surgery. Comparing SG and GB to 
medical treatment, fasting and post-prandial PYY increased similarly after both 
surgical techniques, whereas conservative treatment had no influence on 
plasma PYY levels (Valderas et al., 2010). An increase in fasting and meal-
induced PYY levels has also been observed after BPD-DS, a surgical technique 
that incorporates SG (Hedberg et al., 2011). 
Markedly reduced fasting ghrelin levels were observed after GB in comparison 
to obese and normal-weight controls or to patients with diet-induced weight loss 
(Cummings et al., 2002; Frühbeck et al., 2004a, 2004b; Tritos et al., 2003). No 
differences were observed between diabetic or non-diabetic obese patients 
regarding low preoperative ghrelin levels and postoperative decrease 
(Geloneze et al., 2003). Meal-related and diurnal fluctuations of plasma ghrelin 
seem to be suppressed after surgery (Cummings et al., 2002). Comparing pre- 
and postprandial ghrelin levels, Korner and coworkers could demonstrate an 
increased postprandial suppression of plasma ghrelin in patients submitted to 
GB in comparison to obese controls achieving a profile similar to lean controls 
(Korner et al., 2006, 2005). Yet, contradictory results indicate an unchanged 
fasting plasma ghrelin in weight-stable patients and even an increase in patients 
experiencing active weight loss after GB (Borg et al., 2006; Faraj et al., 2003; 
Holdstock et al., 2003; Nijhuis et al., 2004). Minigastric bypass (MGB) 
represents a variation of GB with a longer gastric pouch and a lateral gastro-
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jejunostomy. Apparently, no effect on fasting plasma ghrelin levels is exerted, 
but excess weight loss correlated negatively with high preoperative fasting 
ghrelin levels (Liou et al., 2008).  
Hypothetically, transient decrease of fasting ghrelin after GB might be 
attributable to vagus nerve dysfunction after surgery, as ghrelin is produced 
mainly in the gastric fundus and secretion depends on vagal stimulation 
(Sundbom et al., 2007). However, pre- and postprandial plasma levels are not 
necessarily associated with a successful surgical outcome regarding weight 
loss or satiety after GB (Christou et al., 2005). Comparable results regarding the 
missing predictive value of fasting plasma ghrelin levels for post-surgical weight 
loss were decribed after gastric banding (Busetto et al., 2006).  
One year after BPD, fasting ghrelin levels were increased in comparison to pre-
operative values (Adami et al., 2004), thus indicating probably a new steady-
state. In another study regarding patients submitted to BPD, plasma ghrelin 
levels also increased after surgery, but circadian pulsatility  was disrupted, in a 
similar fashion as observed in patients submitted to GB (Cummings et al., 
2002).  
A sustained decrease in fasting ghrelin levels was observed after SG in 
comparison to preoperative values (Langer et al., 2005). In a comparative 
study, fasting ghrelin levels decreased and postprandial ghrelin was markedly 
suppressed after SG, whereas no significant changes were demonstrated after 
GB (Karamanakos et al., 2008). Similarly, fasting ghrelin levels were 
significantly suppressed after BPD-DS, if compared to obese patients treated 
with vertical gastroplasty or diet that experienced increased fasting ghrelin 
plasma levels (Kotidis et al., 2006). In another study, resection of the gastric 
fundus added to standard GB suppressed fasting ghrelin in a fashion similar to 
SG, whereas ghrelin levels increased in the group submitted to standard GB. 
Moreover, meal-stimulated secretion of GLP-1 and PYY was more pronounced 
after GB with fundus resection (Chronaiou et al., 2012).  
However, at least the initial effect of bariatric surgery on improvement of insulin 
sensitivity and beta-cell function in obese non-diabetic or diabetic patients might 
be due to caloric restriction and not related to changes in secretion of 
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gastrointestinal hormones, as demonstrated in studies involving controls and 
patients submitted to GB (Isbell et al., 2010) and BPD-DS (Plourde et al., 2014). 
Conversely, a postprandial increase in PYY and GLP-1 was shown 2 – 3 weeks 
after GB, not observed in an age- and BMI-matched control group after a 7-day 
low-calorie diet (Evans et al., 2012), albeit results may have been biased 
because dietary changes in patients in the GB group lasted for already 2 – 3 
weeks. 
 
Pancreatic hormones and metabolic surgery 
As outlined above, hepatic and peripheral insulin resistance represents a key 
feature of T2D and even more so in obese patients. Progression of disease 
leads to beta-cell failure due glucotoxicity, lipotoxicity and deposition of IAPP. 
Loss of incretin function plays an additional role. Consequently, patients with 
IGT or overt T2D can present with high, normal or low insulin plasma levels, 
depending on disease stage and contribution of the different factors. Plasma 
glucagon levels tend to be high due to inadequate or excessive release from 
pancreatic alpha-cells and might contribute to impairment of glucose tolerance.   
In obese patients, whether diabetic or not, high preoperative fasting plasma 
insulin levels related to insulin resistance decrease significantly after all types of 
bariatric surgical procedures including gastric banding, sleeve gastrectomy, 
gastric bypass, and biliopancreatic diversion (Adami et al., 2004; Ballantyne et 
al., 2006; Benaiges et al., 2013; Faria et al., 2013; Gumbs et al., 2005; Mari et 
al., 2006; Pontiroli et al., 2002; Pories et al., 2010, 1992, 1987; Ramos et al., 
2006; Rizzello et al., 2010; Wickremesekera et al., 2005). Mixed-meal induced 
insulin secretion tends to be augmented after surgery (Falkén et al., 2011; le 
Roux et al., 2006; Peterli et al., 2009). Reduced hepatic insulin resistance and 
increased hepatic insulin-induced glucose uptake in obese diabetic and non-
diabetic patients after both GB and SG has been demonstrated by positron 
emission tomography (PET) during an euglycemic hyperinsulinemic clamp 
(Immonen et al., 2014). Besides improvement in insulin sensitivity and reduction 
of insulin resistance, an augmented beta-cell glucose sensitivity after BPD in 
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obese diabetic patients indicates major changes in beta-cell function (Camastra 
et al., 2007). 
Less is known regarding the influence of surgical procedures on glucagon 
secretion. In general, fasting glucagon is not affected after surgery, whereas 
meal-induced response is initially incremented and decreases after one year to 
preoperative values (Falkén et al., 2011).   
 
Research in animal models and humans 
Goto-Kakizaki rats derived originally from glucose intolerant Wistar rats 
submitted to repetitive selective inbreeding (Goto et al., 1976) and have been 
studied extensively as a model for T2D in non-obese humans. They represent 
similar features in comparison to the human pancreatic phenotype in patients 
with T2D (Portha et al., 2009; Seiça et al., 2003a). In hyperglycemic conditions, 
the isolated pancreas of GK rats presents with a blunted pancreatic insulin 
response after stimulation by the incretin hormones GIP and GLP-1 in 
comparison to the pancreas of non-diabetic Wistar rats (Edholm et al., 2009). 
In GK rats, duodenal exclusion without gastric resection ameliorated glycemic 
control in comparison to sham operated controls, as demonstrated by an oral 
glucose tolerance test, three weeks after surgery. No statistically significant 
effect on fasting insulin and GIP (Rubino and Marescaux, 2004) or glucose-
stimulated insulin, GIP and GLP-1 was observed (Pacheco et al., 2007). 
Comparing gastro-jejunal bypass (GJB) to gastro-jejunostomy without duodenal 
exclusion in the same animal model, it could be shown that animals submitted 
to surgery without duodenal exclusion would not experience an ameliorated 
glucose control in comparison to sham surgery or non-operated controls 
(Rubino et al., 2006). A later study in GK rats could show an increase in GLP-1 
secretion after GJB, associated with higher mRNA insulin expression in 
pancreatic islets (de Luis et al., 2012). Duodenal-jejunal bypass (DJB) also 
enhanced beta-cell area and decreased associated fibrosis in comparison to 
sham-operated animals (Speck et al., 2011). Gastric bypass carried out in a 
fashion similar to humans including reduction of gastric volume in addition to 
DJB promoted enhanced expression of the GLP-1 receptor in pancreatic islet, 
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besides augmented fasting GLP-1 levels and reduced insulin resistance (Liu et 
al., 2011). Apparently, DJB in GK rats also up-regulates hepatic insulin 
signaling pathways and down-regulates key regulatory enzymes of 
gluconeogenesis (Sun et al., 2013). 
However, ileal transposition (IT), a surgical technique without duodenal 
exclusion, showed amelioration of glucose control in operated GK rats, 
alongside with a statistically significant rise in GLP-1 after an oral glucose load 
in comparison to sham operated animals (Patriti et al., 2005). Additionally, an 
increased proglucagon expression was demonstrated in the transposed ileal 
segment (Patriti et al., 2007). Comparing duodenal-jejunal exclusion (DJE) to IT 
in the same animal model, a similar post-operative glucose-stimulated increase 
in GLP-1 secretion and improvement of glucose tolerance was observed after 
both surgical techniques. Interestingly, improved glucose tolerance was 
reversible in rats submitted to DJE through administration of Exendin-[9-39], a 
GLP-1 receptor antagonist (Kindel et al., 2009). Similar results regarding 
glucose homeostasis and glucose-stimulated GLP-1 secretion were obtained in 
another study in GK rats comparing BPD without gastric resection to animals 
submitted to IT. No significant differences between groups were observed 
(Zhang et al., 2011). Besides an increment in GLP-1 secretion, IT in GK rats 
promoted myocardial glucose uptake, protein expression of insulin signaling 
pathways, and protein levels of membrane glucose transporter 4 (Yan et al., 
2012).  
In the same rodent model, the effect of SG on glucose homeostasis and fasting 
plasma ghrelin was compared to the effect of a modified duodenal-jejunal 
bypass (MDJB), a technique with duodenal exclusion similar to DJE. 
Interestingly, SG provided better results regarding glucose metabolism and 
reduced fasting plasma ghrelin levels (Li et al., 2009). Combination of duodenal 
exclusion and SG in GK rats showed a more pronounced GLP-1 secretion after 
an oral glucose load in comparison to SG alone. However, both surgical 
techniques obtained similar results regarding decrease of fasting ghrelin and 
glucose-stimulated increase of PYY in comparison to controls (Sun et al., 2012). 
Research in obese University of California at Davis type 2 diabetes mellitus  
(UCD-T2DM) rats, a recent polygenic rodent model for T2D (Cummings et al., 
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2008), revealed a metabolic effect of SG regarding glucose homeostasis, even 
without bypassing any segment of the digestive tract. Further investigation 
revealed also an increase in nutrient-stimulated GLP-1 and PPY secretion, 
alongside with decreased fasting plasma insulin and ghrelin (Cummings et al., 
2012). 
Other rodent models used to study the effects of bariatric and metabolic surgery 
include strains with a single genetic defect like the obese Zucker fatty rat (ZFR) 
due to a simple autosomal recessive gene on chromosome 5. A diabetic 
substrain of the model was obtained by selective inbreeding for impairment of 
glucose homeostasis and denominated Zucker diabetic fatty rat (ZDF) 
(Srinivasan and Ramarao, 2007). Albeit a model with a single genetic defect 
might not correctly represent the polygenic nature of human T2D, male ZDF 
rats are characterized by progression to overt diabetes together with insulin 
resistance and beta-cell apoptosis. After DJB, a decrease in food intake and 
weight gain has been observed, alongside with a meal-induced suppression of 
acylated ghrelin, in the presence of increased fasting plasma ghrelin levels 
(Rubino et al., 2005).  
Insulin sensitivity in ZDF rats submitted to GB was significantly improved in 
comparison to pair-fed controls or animals with ad libitum access to food, in the 
absence of significant changes in visceral or subcutaneous fat assessed by 
magnetic resonance imaging (MRI). Dextrose-stimulated GLP-1 secretion and 
glucose/intralipid-stimulated secretion of PYY was significantly enhanced after 
surgery (Meirelles et al., 2009). In the same animal model, SG with IT, a 
technique without exclusion of the proximal small intestine, induced a similar 
weight loss and improvement in glucose homeostasis in comparison to GB 
(Boza et al., 2011b). However, SG alone also improved glucose homeostasis in 
ZDF rats, even without associated IT (Kadera et al., 2013; Lifante et al., 2012). 
Apparently, SG in ZDF acts through reduction in food intake, suppression of 
plasma ghrelin and increase in glucose-stimulated secretion of GLP-1, GIP and 
PYY, whereas DJB ameliorated glucose homeostasis without significant 
changes in weight gain or effect on mentioned gut hormones. Interestingly, 
postprandial glucagon response was suppressed after DJB, and addition of DJB 
P a g e  | 49 
 
to SG further improved glucose tolerance and decreased weight gain (Patel et 
al., 2013).  
In a non-diabetic rodent model with diet-induced obesity (DIO), the transposition 
of a segment of the distal ileum to the proximal jejunum was able to promote a 
reduced food intake and weight gain in adult Long-Evans rats. In response to an 
oral gavage with D-Glucose, increased GLP-1 levels were observed in 
comparison to sham operated animals. Additionally, gavage with an intralipid 
solution produced an increased stimulated PYY secretion. Post mortem studies 
showed an overexpression of preglucagon mRNA and PYY mRNA in the 
transposed segment (Strader et al., 2005). In a later study, an improvement in 
glucose tolerance after IT was shown in low dose streptozotocin-induced 
diabetic rats and non-diabetic controls with a similar increase in gut hormones 
as described before (Strader et al., 2009). In the same animal model, SG and 
GB enhanced mixed-meal stimulated GLP-1 secretion. Insulin sensitivity 
assessed by hyperinsulinemic euglycemic clamp studies was improved after 
both surgical techniques (Chambers et al., 2011).   
In DIO Sprague-Dawley rats, gastric bypass produced an increase in plasma 
PYY levels, however without affecting GLP-1 plasma levels (Suzuki et al., 
2005). In the same model, weight loss or weight stabilization in comparison to 
an age-matched control group correlated to post-operative decrease in plasma 
ghrelin (Stylopoulos et al., 2005). Nonetheless, gut hormones in DIO rats were 
affected by SG alone and impaired postprandial GLP-1 secretion was restored 
to levels similar to those observed in lean controls (Al-Sabah et al., 2014). In 
other models for DIO using Wistar and Long-Evans rats, no improvement of 
insulin sensitivity was observed after DJB (Kindel et al., 2010), but an enhanced 
beta-cell secretory capacity was demonstrated (Araujo et al., 2012). 
In a non-obese non-diabetic rodent model using Wistar rats, an increase in 
fasting PYY and GLP-1 was observed in animals submitted to jejuno-ileal 
bypass (le Roux et al., 2006) or BPD (Borg et al., 2007). After BPD in the same 
animal model, adaptive processes towards modulation of food intake were 
accompanied by an increased NPY expression in brain tissue (Nadreau et al., 
2006). Comparing SG alone to SG plus IT in non-obese non-diabetic Sprague-
Dawley rats, a similar expression of pancreatic GLP-1 producing cells was 
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observed after both procedures, but only animals submitted to SG plus IT 
showed and enhancement of ileal GLP-1 production (Johannessen et al., 2013). 
In the same rodent model, the length of the transposed ileum determined the 
amplitude of effects on gut hormones and glucose metabolism (Ramzy et al., 
2014). 
Based on the results of IT and its effects on enteroendocrine pathways and 
glucose homeostasis in animal research, de Paula and coworkers started an 
experimental clinical study in 39 diabetic patients with a body mass index from 
23.4 – 35 kg/m2 (DePaula et al., 2008), not considered for bariatric surgery by 
international guidelines (“Gastrointestinal surgery for severe obesity: National 
Institutes of Health Consensus Development Conference Statement.,” 1992). 
Patients were submitted to ileal interposition (II)3 plus SG (II-SG) or II plus 
diverted SG (II-DSG) with a direct anastomosis between the sectioned 
duodenum and the transposed ileal segment. After a mean follow-up of 7 
months, 86.9% achieved an acceptable glycemic control and the remaining 
13.1% improved. In a later publication, both surgical techniques proved to have 
a significant effect on postprandial plasma levels of gastrointestinal hormones. 
After a mean follow-up of 16 months (range 14 – 22 months), meal-stimulated 
secretion of GIP, GLP-1 and PYY increased, whereas plasma ghrelin levels 
were suppressed (DePaula et al., 2009). As expected, insulin sensitivity and 
glucose-stimulated beta-cell function improved significantly after both 
procedures (De Paula et al., 2011; Vencio et al., 2011). An update on results of 
the same center was published in 2012. After a mean follow-up of 39.1 months, 
78.3% of 202 patients achieved a HbA1c <6.5%, without medication (DePaula 
et al., 2012). Another study from a different surgical center evaluated the results 
of II-SG in non-obese and obese patients with type 2 diabetes and showed 
remission (defined as a HbA1c level <6.5%) in 80% of patients, after a mean 
follow-up of 13 months (Tinoco et al., 2011). Using the same surgical technique 
(II-SG) in diabetic Indian patients, weather obese or not, diabetes remission 
was obtained in 47% of 42 patients after 6 months (Kota et al., 2012b). Results 
of II-DSG were markedly better with remission rates of 70.5% in 32 patients 
after a mean follow-up of 13.1 months (Kota et al., 2012a).  
                                                             
3
 Comparable to IT. 
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Based on experimental results of DJB in a lean animal model of type 2 
diabetes, a small clinical study was conducted in 35 diabetic patients without 
substantial excess weight (BMI 28.4±2.9 kg/m2). However, diabetes remission 
defined as HbA1c <7% off medication occurred in only 40% after 12 month of 
follow-up, without any significant weight loss (R. Cohen et al., 2012). Albeit an 
amelioration of glucose homeostasis in some patients, DJB without gastric 
resection did not show a beneficial effect on beta-cell function or insulin 
resistance in another study from the same group (Klein et al., 2012).  
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AIMS AND SCOPE OF INVESTIGATION 
In the present study, we evaluate the effect of sleeve gastrectomy and gastric 
bypass on glycemic control and plasma gut hormone profiles in a lean rodent 
model of type 2 diabetes. Both surgical techniques represent safe and 
established approaches for the treatment of severe and morbid obesity in 
current clinical practice, but are not yet broadly used in lean patients or patients 
with mild obesity or simply overweight. Gastric bypass serves as a model that 
includes duodenal exclusion, whereas sleeve gastrectomy comprises no bypass 
of the gastrointestinal tract. Results are compared to lean non-diabetic rats.  
Additionally, a clinical study in obese patients with impaired fasting glucose and 
type 2 diabetes submitted to sleeve gastrectomy highlights the role of insulin 
resistance in the pathophysiology of glucose metabolism and mechanisms of 
post-surgical recovery. 
Our investigation shall contribute to the understanding of changes in gut 
hormones profiles after accepted bariatric surgical techniques with or without 
duodenal exclusion and their future clinical usefulness in non-severely or 
morbidly obese patients with type 2 diabetes. 
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MATERIAL AND METHODS4 
1. Experimental Study 
1.1. Animals 
Twelve- to 14-week-old male GK rats and age-matched Wistar rats were 
obtained from local breeding colonies at the Laboratory for Experimental 
Research, Faculty of Medicine, University of Coimbra, Coimbra, Portugal 
[Figure.1].  
  Figure 1  12- to 14-week-old male Goto-Kakizaki rats 
All animals were maintained in a controlled environment with day-night cycles of 
12 hours, a temperature of 22 – 24 ºC, and a relative humidity of 50 – 60 
percent. Animals had ad libitum access to water and standard rat chow supplied 
by Charles River, SAFE, France. In the first post-operative days, operated 
animals had additional access to a mixed liquid diet (Forticare®) supplied by 
Nutricia, Danone Group, France.  
The study protocol regarding the use of laboratory animals was approved by the 
Ethics Committee of the Faculty of Medicine of the University of Coimbra, 
Coimbra, Portugal. After completing the study, 30 days after surgery, all animals 
were sacrificed by cervical displacement, according to the procedures approved 
by the Institutional Animal Care and Use Committee.  
 
  
                                                             
4
 Adapted from published articles or manuscripts submitted for publication.  
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1.2. Study Protocol and Surgical Techniques 
Forty non-obese diabetic GK rats were randomly assigned to the following 
groups: control (GKC), sham surgery (GKSS), sleeve gastrectomy (GKSG), and 
gastric bypass (GKGB). Wistar rats (n=10) served as an additional non-diabetic 
control group (WIC). Before surgery or entering the control group, venous blood 
was sampled from the tail vein for determination of blood glucose level, glycated 
hemoglobin, cholesterol, and triglycerides, after an overnight fast, and, without 
previous fasting, for random glycemia.  
Animals assigned to surgery (GKSS, GKSG, GKGB) were operated under intra-
muscular anesthesia using ketamine (75 mg / kg bodyweight, Pfizer Inc., New 
York, NY, USA) and chlorpromazine (3 mg / kg bodyweight, Laboratórios 
Vitória, Amadora, Portugal). After shaving the abdomen, skin was prepped with 
a 4% polividone-iodine solution (MEDA Pharma, Lisbon, Portugal). A midline 
incision was performed and the abdominal cavity entered. Surgery was 
performed accordingly to the randomization of animals. After completing 
surgery and rinsing the abdomen with sterile saline, meloxicam (1 mg / kg 
bodyweight, Boehringer Ingelheim GmbH, Ingelheim, Germany) in sterile saline 
was left in the peritoneal cavity for post-operative analgesia. The abdominal wall 
was closed in all animals by continuous mass closure with a 3/0 short-term 
absorbable suture of braided and coated polyglycolic acid (Safil Quick®, B 
Braun, Aesculap AG, Tuttlingen, Germany). Post-operative care included 
subcutaneous analgesia with meloxicam (1 mg / kg bodyweight) and oral 
antibiotics (doxycycline, 5 mg / kg bodyweight, Pfizer Inc., New York, NY, USA) 
mixed to drinking water during 5 days. Animals dying from post-operative 
complications (n=12) were replaced to maintain the original number of animals 
in groups. 
Blood samples were repeated at four weeks for the same parameters as 
described above. Three to four days later, after an overnight fast, all animals 
were fed 3 cc of a mixed liquid diet (Forticare®) supplied by Nutricia, Danone 
Group, France. Blood samples were drawn by intra-cardiac puncture in the 
anesthetized animal before and after the oral fed at 10, 20, 30, 40, and 60 
minutes for the dosage of plasma concentrations of the following pancreatic and 
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gut hormones: insulin, glucagon, GLP-1, PYY, and ghrelin. Animals were 
sacrificed afterwards as described above.  
 
1.2.1 Sham Surgery  
In animals assigned to sham surgery, the stomach was mobilized and a 3 cm 
incision in anterior gastric wall was performed. To resemble more complex 
surgical techniques, an interval of 20 minutes was observed before closing the 
gastric incision with a continuous extra-mucosal technique using a 4/0 mid-term 
absorbable synthetic glyconate monofilament thread (Monosyn®, B Braun, 
Aesculap AG, Tuttlingen, Germany).  
 
1.2.2 Sleeve Gastrectomy 
Sleeve gastrectomy was performed by dissection of the greater curvature 
including the lower part of the stomach and the aglandular forestomach with 
ligation of the short gastric vessels accordingly to a technique described before 
(de Bona Castelan et al., 2007; Lopez et al., 2009) [Figure 2A].  
 
Figure 2  Rat GKSG#5: Sleeve gastrectomy 
The stomach was sectioned over a bulldog clamp to fashion the gastric sleeve. 
The operative specimen, including most of the forestomach, was removed 
[Figure 2B]. The gastric wound was closed with a continuous invaginating extra-
mucosal suture with a 4/0 mid-term absorbable synthetic glyconate 
monofilament thread as described above (Monosyn®, B Braun, Aesculap AG, 
Tuttlingen, Germany) [Figure 2C]. 
 
A B C 
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1.2.3 Gastric Bypass 
Gastric bypass was done in a similar fashion as in humans and described in 
rats (Meguid et al., 2004). The mid portion of the stomach of animals allocated 
to gastric bypass was freed from adhesions on the greater and lesser curvature. 
Horizontal section of the stomach was performed leaving only a small rim of 
glandular stomach on the proximal part [Figure 3A]. The distal stomach was 
closed using a 4/0 mid-term absorbable monofilament suture (Monosyn®, B 
Braun, Aesculap AG, Tuttlingen, Germany), in an invaginating extra-mucosal 
technique [Figure 3B].   
 
Figure 3  Rat GKGB#4 Gastric bypass 
Beginning at the lesser curvature, the proximal stomach was closed in a similar 
fashion, leaving a small opening close to the greater curvature to perform the 
gastro-jejunal anastomosis. The angle of Treitz was identified and 10 cm were 
measured on the proximal jejunum. The jejunal loop was brought up to the 
proximal stomach and a 2 cm incision was made on the antimesenteric border 
of the bowel wall. The gastro-jejunal anastomosis was performed in an end-to-
side fashion with a extramucosal continuous suture using a 5/0 mid-term 
absorbable synthetic monofilament suture of glyconate (Monosyn®, B Braun, 
Aesculap AG, Tuttlingen, Germany) [Figure 3C]. No mesenteric defects were 
closed. 
 
1.3. Glucose, Lipids, Glycated Hemoglobin and Hormones 
Glycemia was determined in the tail vein through a glucose-oxidase reaction 
using a commercially available glucometer with appropriate test strips 
(Glucometer Elite, Bayer SA, Portugal). Serum cholesterol and triglycerides 
were determined using a portable analyzer (Accutrend GCT, Roche 
A B C 
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Diagnostics, F. Hoffmann-La Roche Ltd., Switzerland). Glycated hemoglobin 
was measured using a Siemens DCA 2000+ Analyzer (Siemens AG, Germany). 
GLP-1, PYY, ghrelin and glucagon were analyzed by competitive enzyme-linked 
immunosorbent assays (Wako Pure Chemical Industries Ltd., Osaka, Japan 
and Peninsula Laboratories, LLC, Bachem Group, San Carlos, CA, USA), using 
specific antibodies that bind to sample and biotinylated tracer, respectively. A 
96-well microtiter plate coated with a secondary antibody capturing the primary 
antibody bound to sample or tracer was subsequently submitted to a reaction of 
captured tracer with HRP-conjugated streptavidin, which produces a colored or 
fluorescent product after adding a substrate. 
Plasma insulin was determined in a similar fashion using a non-competitive 
solid phase two-site enzyme immunoassay based on the sandwich technique 
(Mercodia AB, Uppsala, Sweden) where insulin in the sample reacts to specific 
antibodies bound to the microtiter plate and peroxidase-conjugated antibodies 
in a solution producing a colored solution together with a substrate. 
Duplicate samples of all gut hormones were measured using a microplate 
reader with Gen5TM software (Synergy HT, Biotek, Winooski, VT, USA). 
Insulin sensitivity was assessed by a mathematical model (quantitative insulin 
sensitivity check index [QUICKI]) calculating the reciprocal index of the sum of 
logarithms for plasma glucose in mg/dL and plasma insulin in μU/mL as 
described elsewhere (Katz et al., 2000; Muniyappa et al., 2009). The area under 
the curve (AUC) was calculated for post-prandial insulin and glucagon secretion 
using the trapezoidal method. 
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2. Clinical Study 
2.1 Patients 
From February 2008 to July 2010, SG as a stand-alone treatment for severe or 
morbid obesity was performed in 10 patients with T2D and 13 patients with IFG 
as defined by American Diabetes Association criteria (blood sugar ≥ 126 mg/dl 
or ≥ 100 mg and ≤ 125 mg/dl, respectively, or on antidiabetic medication). Six 
patients were on oral antidiabetics. 19 patients were female (82.6%) and mean 
age was 45.3±2.1 years (20 – 62 years). All patients were assessed 
preoperatively by a multidisciplinary team including surgeon, nutritionist and 
psychologist. Other medical specialties were involved accordingly to clinical 
requirements. Pre-operative work-up included ECG, chest radiography, upper 
endoscopy, abdominal ultrasound and blood testing with endocrine screening. 
After signing an informed consent, patients were submitted to laparoscopic SG. 
Peri-operatively, insulin was administered subcutaneously to control blood 
sugar levels. No post-operative complications occurred and all patients were 
dismissed from hospital on a liquid diet on day 2 after surgery.  
Patients were reassessed at the outpatient department at day 9 and 1, 3, 6, 12, 
and 24 months after surgery. A soft diet was started in the third week after 
surgery and a solid diet 2 – 3 weeks later.  At one month, subcutaneous insulin 
accordingly to blood sugar levels could be discontinued in all patients. BMI, 
fasting glycemia and fasting insulin (assessed by standard laboratorial methods 
in venous blood) were registered before and 3, 12 and 24 months after surgery. 
Patients with fasting blood glucose (FBG) <100 mg/dl without medication were 
considered in remission. Mean preoperative BMI was 41.4±1.1 kg/m2 (range 
33.45 – 52.4 kg/m2), FBG was 122.9±6.7 mg/dl (range 976 – 254 mg/dl) and 
fasting insulin was 22.6±2.4 μIU/ml (range 4.6 – 41.8 μIU/ml). Beta-cell function 
and insulin resistance were calculated from fasting glucose and insulin using 
the updated homeostasis model assessment (HOMA) calculator version 2.2, 
available from the Diabetes Trials Unit website (http://www.dtu.ox.ac.uk) (Levy 
et al., 1998; Matthews et al., 1985). Twenty-two out of 23 patients were 
                                                             
5
 One patient with BMI < 35 kg/m2 at date of surgery due to standard pre-operative diet. 
6
 One patient on oral antidiabetics with fasting glycemia < 100 mg/dl.  
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available for follow up at 3 months, 20 out of 23 patients at 12 months, and 18 
out of 23 patients at 24 months. 
 
2.2 Surgical Technique 
Laparoscopic SG was carried out under general anesthesia, eventually 
combined with a thoracic epidural catheter, in a standardized fashion using a 4-
port technique and a Nathanson liver retractor inserted through a separate 
epigastric incision.  
 
Figure 4  Patient 9: Gastric mobilization 
During surgery, special attention was given to a complete mobilization of the 
gastric fundus and the His’ angle, with complete dissection of retrogastric 
adhesions [Figure 4A – 4C].  
 
Figure 5  Patient 9: Gastric transection and oversewing of the staple line 
The stomach was transected over a 36F bougie beginning 4 – 6 cm from the 
pylorus using an endoscopic stapler with 6 cm cartridges and adequate staple 
height regarding the thickness of the gastric wall [Figure 5 A]. The staple line 
was oversewn with a running suture using a 2/0 mid-term absorbable synthetic 
glyconate monofilament thread in all patients [Figure 5B, 5C]. A suction drain 
was left routinely in the beginning of the experience. 
  
A B C 
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3. Statistical Analysis 
All data are presented as mean ± standard error of the mean (SEM) regarding 
the number of experiments described. The Shapiro-Wilk test was used to 
assess if samples were extracted from a variable that follows a normal 
distribution. For samples extracted from normally distributed variables, the 
Student’s t-test was used to compare means of two independent samples. For 
non-normally distributed variables, the non-parametric Mann-Whitney test was 
used to reject or keep the null hypothesis that there were no differences in 
means of groups (H0: μ1 = μ2). Differences were considered statistically 
significant at a level of 95% (p < 0.05).  
To reduce type I errors induced by repeated t-tests, analysis of variance 
(ANOVA) was employed to describe differences between more than two groups 
regarding the same variable or repeated measures of a variable in the same 
group, if normal distribution and homogeneity of variance assessed by the 
modified Levene’s test could be assumed. The Tukey’s HSD (honest significant 
difference) test was used to perform post-hoc comparisons between samples. 
Variables that presented either with non-normal distribution or 
heteroscedasticity were analyzed using the non-parametric Kruskal-Wallis and 
post-hoc analysis including multiple pairwise comparisons using the Steel-
Dwass-Critchlow-Fligner procedure test (Adams et al., 2009; Ferreira et al., 
2012; Kruskal and Wallis, 1952; Van Hecke, 2010). 
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RESULTS7 
1. Experimental Study 
1.1. Weight and Lipids 
Wistar rats were heavier than age-matched GK rats [Table 1]. Animals in control 
groups (WIC, GKC) or submitted to sham surgery (GKSS) sustained statistically 
significant weight gain during the observation period. No significant weight 
changes occurred in the groups submitted to SG (GKSG) or GB (GKGB), if 
compared to pre-operative data [Table 1].  
Pre-operative values for serum cholesterol were similar in all groups. Rats 
submitted to gastric bypass experienced a small but statistically significant 
amelioration of pre-operative values (p < 0.005), whereas rats submitted to SG 
did not sustain any significant alteration [Table 1]. Multiple comparison by 
ANOVA with post-hoc analysis revealed that, in comparison to both control 
groups (WIC, GKC) and GKSS, post-operative serum cholesterol was 
significantly lower in GKGB.  
All groups sustained a decrease of serum triglycerides during the observation 
period [Table 1]. However, only in rats submitted to SG the amelioration of 
serum triglycerides was statistically significant if compared to pre-operative 
values (p < 0.05). The comparison of serum triglycerides between groups at the 
end of the observation period showed no statistically significant difference 
[Table 1].  
 
1.2. Glucose Metabolism 
Fasting glycemias at baseline were similar in all groups (78±2.1 - 106±13.0 
mg/dl), except for GKSS. Due to maturation of young animals, WIC presented 
with significantly lower fasting glycemias (72±3.9 mg/dl) than GK rats in all 
groups (106±4.9 - 136±9.2 mg/dl) at the end of the observation period. Random 
glycemias at the end of the observation period were also lower in WIC (87±2.4 
                                                             
7
 Adapted from published articles or manuscripts submitted for publication.  
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mg/dl) in comparison to GK rats (p<0.02), except for rats submitted to SG 
(106±12.3 mg/dl) [Table 1].  
 
Table 1  Experimental  study in 50 rats: Weight, blood glucose, glycated hemoglobin and lipids 
    at baseline and four weeks after surgery 
 WIC GKC GKSS GKSG GKGB 
Weight (g) 
baseline 
328±11.9
a 
256±9.0 270±13.4 277±7.3 284±9.2 
Weight (g) 
4 weeks 
388±9.1***
b 
308±8.0*** 330±11.5** 296±17.8 303±12.5 
Fasting glycemia 
(mg/dl) baseline 
78±2.1
c
 102±11.3 110±10.9 97±8.3 106±13.0 
Fasting glycemia 
(mg/dl)  4 weeks 
72±3.9
d
 106±4.9 111±5.7 112±5.3* 136±9.2* 
Random glycemia 
(mg/dl) 4 weeks 
87±2.4
e 
169±30.4 153±20.5 106±12.3 129±13.2 
HbA1c (%)  
baseline 
3.5±0.1
d 
4.8±0.3 4.8±0.3 5.1±0.3 5.0±0.3 
HbA1c (%) 
4 weeks 
3.3±0.1
b 
5.0±0.2 4.6±0.2 3.8±0.1***
f 
4.0±0.2*
g
 
Cholesterol (mg/dl) 
baseline 
161±2.1 159±1.6 164±1.2 161±1.4 163±1.9 
Cholesterol (mg/dl) 
4 weeks 
162±1.4 164±1.4 162±1.5 158±1.9 156±1.1***
h 
Triglycerides (mg/dl) 
baseline 
123±5.5 128±11.2 142±18.3 134±8.8 123±4.2 
Triglycerides (mg/dl) 
4 weeks 
115±5.0 114±6.4 116±12.0 106±6.3* 108±11.6 
 
WIC (= Wistar rats – control), GKC (= Goto-Kakizaki rats – control), GKSS (= Goto-Kakizaki rats – sham 
surgery), GKSG (= Goto-Kakizaki rats – sleeve gastrectomy), GKGB (= Goto-Kakizaki rats – gastric 
bypass). All values are given with standard error of the mean (SEM). The Mann-Whitney test or Student’s 
t-test were used to assess for differences between baseline and values at the end of the observation 
period (*p<0.05, **p<0.01, ***p<0.005). The Kruskal-Wallis test or ANOVA were used to assess for 
intergroup differences (
a
p<0.05 in comparison to GKC, GKSG, GKGB; 
b
p<0.05 in comparison to GKC, 
GKSS, GKSG, GKGB; 
c
p<0.05 in comparison to GKSS; 
d
p≤0.005 in comparison to GKC, GKSS, GKSG, 
GKGB; 
e
p<0.02 in comparison to GKC, GKSS, GKGB; 
f
p<0.05 in comparison to GKC, GKSS; 
g
p<0.05 in 
comparison to GKC; 
h
p<0.05 in comparison to WIC, GKC, GKSS).  
 
Overall glycemic control assessed by determination of HbA1c was significantly 
improved in GK rats submitted to SG (p < 0.005) or GB (p < 0.05), when 
compared to pre-operative values [Table 1]. Wistar rats also improved their 
levels of HbA1c during the observation period, but without statistical 
significance. No amelioration was observed in either sham operated or control 
group GK rats. Comparing overall glycemic control at the end of the observation 
period between groups, GKSG rats showed statistically significant improvement 
in comparison to GKC and GKSS [Table 1]. No significant difference in 
comparison to animals submitted to GB was observed. Despite of statistically 
significant amelioration of overall glycemic control in GK rats submitted to either 
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SG or GB, animals in these two groups did not achieve a glycemic control 
comparable to WIC (p < 0.05). 
 
1.3. Insulin and Insulin Sensitivity 
Fasting plasma insulin levels were similar in Wistar and GK rats, whether 
submitted to surgery or not. Meal induced plasma insulin concentrations at 20 
minutes were significantly higher in GK rats (all groups) in comparison to WIC 
(p<0.05). At 30 minutes, plasma insulin was highest in GKSG (17.48±0.75 μg/L; 
p<0.05 in comparison to all other groups) and lowest in GKGB (9.21±0.39 μg/L). 
Similar results were observed at 40 minutes. However, at 60 minutes both 
GKSG and GKGB presented with lower plasma insulin than other groups 
(5.95±0.28 and 4.77±0.63 μg/L; p<0.05). Time series revealed a significant rise 
in comparison to baseline at 20 minutes in all groups (p<0.05), but whereas 
GKC and GKSS maintained similar values throughout all following timepoints, a 
significant reduction in plasma insulin concentration was observed in WIC, 
GKSG and GKGB at 60 minutes in comparison to the previous timepoint 
(p<0.05) [Figure 6].  
Total insulin secretion during the first 60 minutes after a liquid mixed-meal 
expressed as AUC was highest in GKC (614±18.3 μg L-1 h; p<0.05 in 
comparison to GKSS, GKGB) and lowest in GKGB (396±15.3 μg L-1 h; p<0.05 
in comparison to all other GK). Differences between Wistar and GK rats in all 
groups were not statistically significant [Table 2]. 
Insulin sensitivity was assessed using QUICKI as described above. GK rats in 
the control group and submitted to sham surgery presented with a lower insulin 
sensitivity (0.2601±2.5-3 and 0.25±5.3-3, respectively) than Wistar rats 
(0.284±1.9-3; p<0.05). GKSG and GKGB had slightly improved indexes in 
comparison to GKC and GKSS, and no significant differences in comparison to 
Wistar rats were observed [Table 2]. 
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Figure 6  Insulin – meal-induced response. WIC (= Wistar rats – control), GKC (= Goto-Kakizaki rats – 
control), GKSS (= Goto-Kakizaki rats – sham surgery), GKSG (= Goto-Kakizaki rats – sleeve gastrectomy), 
GKGB (= Goto-Kakizaki rats – gastric bypass). Kruskal-Wallis test with post-hoc analysis: *p<0.05 in 
comparison to GKGB; 
**
p<0.05 in comparison to GK (all subgroups); 
#
p<0.05 in comparison to GKSS, 
GKSG, GKGB; 
$
p<0.05 in comparison to GKSG, GKGB; 
##
p<0.05 in comparison to all other groups; 
&
p<0.05 in comparison to WIC, GKC, GKSG; 
£
p<0.05 in comparison to GKSS, GKGB; 
§
p<0.05 in 
comparison to WIC, GKC; 
&&
p<0.05 in comparison to WIC, GKSG, GKGB; 
££
p<0.05 in comparison to GKC, 
GKSS; 
§§
p<0.05 in comparison to WIC, GKC, GKSS. 
a
p<0.05 in comparison to baseline; 
b
p<0.05 in 
comparison to previous timepoint. 
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1.4. Glucagon and Glucagon-Insulin Ratio 
GK rats submitted to gastric bypass presented with higher fasting plasma 
glucagon than all other groups (405.86±30.14 pg/mL; p<0.05 in comparison to 
GKC, GKSG) and maintained this pattern at 10 and 20 minutes after the test 
meal. However, at 30 minutes plasma glucagon increased significantly in rats 
submitted to SG (676.04±18.01 pg/mL), as well as, to a lesser extent, in rats 
submitted to GB (652.37±39.69 pg/mL). Hormone levels remained stable at a 
high level in both groups up to 60 minutes (p<0.05 in comparison to WIC, GKC, 
GKSS for GKSG; p<0.05 in comparison to GKC, GKSS for GKGB). In all control 
groups, a slight and not statistically significant increase in plasma glucagon was 
observed at 30 minutes, without any further change [Figure 7]. Total glucagon 
secretion during the postprandial period described as AUC was significantly 
higher in GKSG (29.9±0.8 ng mL-1 h) and GKGB (31.5±1.7 ng mL-1 h) in 
comparison to GKC (15.0±3.0 ng mL-1 h) and GKSS (18.1±2.0 ng mL-1 h) [Table 
2]. 
 
Table 2   Experimental study in 50 rats: Insulin sensitivity, plasma insulin, and glucagon at four 
   weeks after surgery 
 WIC GKC GKSS GKSG GKGB 
Insulin sensitivity (QUICKI) 
4 weeks  
0.284±1.9
-3 a 
0.2601±2.5
-3
 0.25±5.3
-3
 0.2678±6.4
-3
 0.2659±4.4
-3
 
Insulin AUC (μg L
-1
 h) 
4 weeks 
532±29.3
 
614±18.3
b 
521±12.6 592±19.6
c 
396±15.3
d 
Glucagon AUC (ng ml
-1
 h) 
4 weeks 
22.9±2.7 15.0±3.0 18.1±2.0 29.9±0.8
a 
31.5±1.7
a 
 
WIC (= Wistar rats – control), GKC (= Goto-Kakizaki rats – control), GKSS (= Goto-Kakizaki rats – sham 
surgery), GKSG (= Goto-Kakizaki rats – sleeve gastrectomy), GKGB (= Goto-Kakizaki rats – gastric 
bypass), AUC (= area under the curve). All values are given with standard error of the mean (SEM). The 
Kruskal-Wallis test was used to assess for intergroup differences (
a
p<0.05 in comparison to GKC, GKSS; 
b
p<0.05 in comparison to GKSS; 
c
p<0.05 in comparison to GKGB; 
d
p<0.05 in comparison to GKC, GKSS, 
GKSG).  
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Figure 7  Glucagon – meal-induced response. WIC (= Wistar rats – control), GKC (= Goto-Kakizaki rats – 
control), GKSS (= Goto-Kakizaki rats – sham surgery), GKSG (= Goto-Kakizaki rats – sleeve gastrectomy), 
GKGB (= Goto-Kakizaki rats – gastric bypass). Kruskal-Wallis test with post-hoc analysis: *p<0.05 in 
comparison to GKC, GKSG; 
#
p<0.05 in comparison to WIC, GKC, GKSS; 
**
p<0.05 in comparison to GKC, 
GKSS. 
a
p<0.05 in comparison to baseline; 
b
p<0.05 in comparison to previous timepoint; 
c
p<0.01 in 
comparison to baseline; 
d
p<0.01 in comparison to baseline. 
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Calculation of glucagon-insulin ratio (GIR) revealed higher values for GKGB in 
comparison to GKC and GKSS at baseline (p<0.05) and to GKC, GKSS and 
GKSG (p<0.05) at 10 minutes after the test meal. However, a significant 
decrease in GIR occurred at 20 minutes (p<0.05). At this timepoint, WIC 
maintained a stable GIR (1.0-4±1.68-5) in comparison to previous timepoints, 
significantly higher (p<0.05) than GIR in GK rats (all groups). However, at all 
following timepoints up to 60 minutes GKGB showed an increased GIR in 
comparison to all control groups (p<0.05). GK rats submitted to sleeve 
gastrectomy showed a significant increase in GIR at 60 minutes (1.26-4±6.1-6), 
achieving a ratio similar to GKGB, and higher than other groups (p<0.05 in 
comparison to WIC, GKC, GKSS) [Figure 8]. 
 
1.5. Ghrelin 
Regarding fasting ghrelin, no differences between groups were observed. 
However, after administration of a mixed liquid meal as described above, GK 
rats submitted to SG or GB sustained a significant decrease in plasma ghrelin, 
30 minutes after the test meal that was maintained up to 60 minutes, without 
any further significant changes. WIC showed a similar pattern, whereas GKC 
and GKSS sustained no significant change in plasma ghrelin at the defined time 
points [Figure 9]. 
Ten and 20 minutes after the test meal, no difference in plasma ghrelin were 
observed between groups. At 30 min, WIC, GKSG, and GKGB showed a 
significant decrease in comparison to GKC. At 40 minutes, plasma ghrelin 
levels were significantly lower in GKSG in comparison to WIC, GKC and GKSS. 
Both GKSG and GKGB expressed significantly lower plasma ghrelin levels in 
comparison to control groups (WIC, GKC), 60 minutes after the test meal 
[Figure 9]. 
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Figure 8  Glucagon-insulin ratio – meal-induced response. WIC (= Wistar rats – control), GKC (= Goto-
Kakizaki rats – control), GKSS (= Goto-Kakizaki rats – sham surgery), GKSG (= Goto-Kakizaki rats – 
sleeve gastrectomy), GKGB (= Goto-Kakizaki rats – gastric bypass). Kruskal-Wallis test with post-hoc 
analysis: *p<0.05 in comparison to GKC, GKSS; 
**
p<0.05 in comparison to GKC, GKSS, GKSG; 
#
p<0.05 in 
comparison to GK (all subgroups); 
$
p<0.05 in comparison to GKC; 
&
p<0.05 in comparison to WIC, GKC, 
GKSS. 
a
p<0.05 in comparison to baseline; 
b
p<0.05 in comparison to previous timepoint. 
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Figure 9  Ghrelin – meal-induced response. WIC (= Wistar rats – control), GKC (= Goto-Kakizaki rats – 
control), GKSS (= Goto-Kakizaki rats – sham surgery), GKSG (= Goto-Kakizaki rats – sleeve gastrectomy), 
GKGB (= Goto-Kakizaki rats – gastric bypass). Kruskal-Wallis test with post-hoc analysis: *p<0.05 in 
comparison to GKC; **p<0.05 in comparison to WIC, GKC, GKSS; 
#
p<0.05 in comparison to WIC, GKC. 
b
p<0.05 in comparison to previous timepoint; 
c
p<0.005 in comparison to baseline; 
d
p<0.005 in comparison 
to previous timepoint. 
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1.6. Peptide Tyrosine Tyrosine 
Wistar rats presented with significantly higher fasting PYY levels than GK rats, 
independent of allocated treatment. Postprandial, there was a significant rise of 
plasma PYY in WIC, 30 minutes and 60 minutes after the test meal. GK rats in 
both control groups showed a slow rise in postprandial PYY, beginning at 40 
minutes. However, GKGB showed a significant rise in PYY levels at all time 
points, starting as early as ten minutes postprandially. GKSG showed a similar 
pattern, starting 20 minutes after the test meal [Figure 10]. 
No significant differences in plasma PYY were observed between WIC and 
GKGB, ten minutes after the test meal. At 20 minutes, GK rats in both control 
groups (GKC, GKSS) had significantly lower plasma PPY levels than all other 
groups. At this time point, no differences were observed between WIC and 
GKSG or GKGB. GK rats in both control groups (GKC, GKSS) maintained 
significantly lower plasma PYY at all time points from 20 minutes onwards, in 
comparison to WIC and GK rats allocated to SG or GB. However, GKGB 
showed significantly higher levels in postprandial plasma PYY than GKSG, up 
to 60 min after the test meal [Figure 10]. 
 
1.7. Glucagon-like Peptide-1  
Fasting levels of GLP-1 were higher in GK rats in comparison to Wistar rats, 
particularly in animals submitted to SG or GB (p<0.05). After administration of 
the test meal, a significant rise in plasma GLP-1 was observed in WIC, as early 
as ten minutes postprandial, with another significant increment during the next 
ten minutes. GKSG experienced a similar rise in GLP-1 after the test meal, 
starting a little later at 20 min, whereas GKGB sustained a significant increment 
in plasma GLP-1 at 30 min, reaching a plateau thereafter. Only a very small 
meal-induced rise in plasma GLP-1 was observed in GK rats in both control 
groups [Figure 11]. 
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Figure 10  PYY – meal-induced response. WIC (= Wistar rats – control), GKC (= Goto-Kakizaki rats – 
control), GKSS (= Goto-Kakizaki rats – sham surgery), GKSG (= Goto-Kakizaki rats – sleeve gastrectomy), 
GKGB (= Goto-Kakizaki rats – gastric bypass). Kruskal-Wallis test with post-hoc analysis: *p<0.05 in 
comparison to GKC, GKSS, GKSG, GKGB; 
#
p<0.05 in comparison to GKC, GKSS, GKSG; 
$
p<0.05 in 
comparison to GKC, GKSS; 
&
p<0.05 in comparison to GKSG; 
§
p<0.05 in comparison to GKSG, GKGB; 
**p<0.05 in comparison to all other groups. 
a
p<0.05 in comparison to baseline; 
b
p<0.05 in comparison to 
previous timepoint; 
c
p<0.005 in comparison to baseline, 
d
p<0.005 in comparison to previous timepoint. 
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Figure 11  GLP-1 – meal-induced response. WIC (= Wistar rats – control), GKC (= Goto-Kakizaki rats – 
control), GKSS (= Goto-Kakizaki rats – sham surgery), GKSG (= Goto-Kakizaki rats – sleeve gastrectomy), 
GKGB (= Goto-Kakizaki rats – gastric bypass). Kruskal-Wallis test with post-hoc analysis: *p<0.05 in 
comparison to GKSS, GKSG, GKGB; 
**
p<0.05 in comparison to GKC, GKSS; 
$
p<0.05 in comparison to 
GKSS; 
#
p<0.05 in comparison to GKC, GKSS, GKSG; 
§
p<0.05 in comparison to all other groups. 
a
p<0.05 
in comparison to baseline; 
b
p<0.05 in comparison to previous timepoint. 
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Plasma levels of GLP-1 reached similar values in Wistar and GKSG or GKGB 
as soon as ten minutes postprandial. GLP-1 levels in these three groups were 
significantly higher in comparison to GK rats in both control groups at all time 
points postprandial. Plasma GLP-1 was significantly higher in GKSG and GKGB 
when compared to Wistar rats, 30 and 40 minutes after the test meal. However, 
no more significant differences could be observed between these three groups, 
60 minutes postprandial [Figure 11]. 
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2. Clinical study 
After SG, a significant decrease in BMI occurred, as early as 3 month after 
surgery (BMI 33.0±1.0 kg/m2). Maximum weight loss occurred until one year 
after surgery (BMI 27.8±0.7 kg/m2) and remained stable at 2 years of follow-up 
(BMI 28.3±0.8 kg/m2). Post-operative BMI was significantly lower than 
preoperative BMI at all time points (p<0.001, ANOVA with post-hoc analysis) 
[Figure 12].  
 
Figure 12  Clinical study in 23 patients submitted to sleeve gastrectomy: Pre- and post-operative body 
mass index, fasting blood glucose, fasting insulin, insulin resistance, and beta-cell function. BMI (= body 
mass index). ANOVA and Tukey HSD post-hoc analysis (Kruskal-Wallis test with post-hoc analysis for 
fasting insulin and insulin resistance): *p<0.05 in comparison to baseline; **p<0.001 in comparison to 
baseline; 
#
p<0.01 in comparison to results at 3 months; 
&
p<0.05 in comparison to results at 3 months. 
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Fasting blood glucose decreased from 122.9±6.7 mg/dl to 93.0±4.0 mg/dl (3 
months), 88.3±2.7 mg/dl (12 months), and 89.8±2.9 mg/dl (24 months). 
Differences between all post-operative time points and pre-operative values 
were statistically significant (p<0.001, ANOVA with post-hoc analysis), but after 
3 months of follow-up, fasting glycemias remained stable, despite continuing 
weight loss until 12 months of follow-up [Figure 12]. In 87.5% of patients, fasting 
blood glucose normalized completely to <100 mg/dl. Concomitantly, fasting 
insulin fell from 22.6±2.4 μIU/ml pre-operatively to 8.7±1.1 μIU/ml at 3 months, 
6.5±0.9 μIU/ml at 1 year, and 5.6±1.1 μIU/ml at 2 years. Statistical analysis 
showed a significant decrease as early as 3 months after surgery, without any 
significant changes thereafter (p<0.001, Kruskal-Wallis-Test) [Figure 12]. 
Mean pre-operative beta-cell function calculated by the updated homeostasis 
model assessment using a computer program (HOMA2), was slightly above 
normal (117.8±9.9%), but three patients presented with a beta-cell function 
<40%, whereas in all other patients function was >70%. During follow-up, mean 
beta-cell function decreased slightly but not significantly to 105.1±13.2% at 3 
months. 
 
Table 3  Body mass index, beta-cell function and insulin resistance in three patients with 
   impaired pre-operative beta-cell function 
 
P1 
pre-op. 
P1 
2 years 
P2 
pre-op. 
P2 
2 years 
P3 
pre-op. 
P3 
2 years 
BMI (kg/m
2
) 33.9* 26.0
 
45.1 29.3 36.6 29.7 
FBG (mg/dl) 137 109
 
143 82 254 118 
Fasting insulin (µIU/ml) 5.6 4.3 8.1 9.9 14.0 9.8 
Beta-cell function (%) 33.3 43.8 39.8 66.5 21.7 50.6 
Insulin resistance 0.8 0.6 1.2 0.4 2.4 0.9 
 
BMI (= body mass index), FBG (= fasting blood glucose), P1/2/3 (= patient 1/2/3). *Patient 1 presented 
with a BMI < 35 kg/m2 at surgery due to standard pre-operative low-calorie diet. Patients available for 
follow-up: 22/23 at 3 months; 20/23 at 12 months; 18/23 at 24 months. 
 
A significant decline in beta-cell function (p<0.05) was observed at 1 year 
(79.6±5.0%) and at 2 years (78.4±9.8%) [Figure 12]. Interestingly, there was a 
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slight improvement in patients with a very low pre-operative beta-cell function 
[Table 3]. Insulin resistance dropped sharply during the first three months from 
3-fold increased mean pre-operated values (3.05±0.31) to 1.14±0.13 (p<0.001). 
Another slight decrease was observed during the first year after surgery 
(0.72±0.06, p<0.05), stabilizing thereafter (0.75±0.13) [Figure 12]. Before 
surgery, 69.6% of patients presented with a markedly increased insulin 
resistance (>2.0) that decrease to normal or below-normal values (<1.0) in 
86.7%. 
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DISCUSSION8 
In our lean animal model of T2D, overall glycemic control assessed by HbA1c 
levels improved after SG and GB. Surprisingly, meal-induced insulin secretion 
diminished after surgery, particularly in rats submitted to GB. However, the 
reduction in insulin secretion was accompanied by increased insulin sensitivity. 
Postprandial glucagon secretion was significantly enhanced after surgical 
procedures, both in comparison to GKC and GKSS rats, as well as non-diabetic 
Wistar rats. In GKGB, GIR started to increase 30 minutes after the test meal 
and remained high throughout the observation period. GKSG showed a similar 
high GIR at 60 minutes. Meal-induced plasma levels of ghrelin, PYY, and GLP-
1 were significantly modified by surgical interventions. Although there was no 
difference in fasting plasma ghrelin levels between groups, WIC and GK rats 
submitted to either SG or GB sustained a similar postprandial decrease in 
plasma ghrelin. Wistar rats presented with different levels in fasting PYY and 
GLP-1 in comparison to GK rats. However, meal induced response was similar 
in Wistar and in GK rats submitted to SG or GB. GK rats in the control group 
(GKC) or submitted to sham surgery (GKSS) sustained no improvement of 
glucose metabolism during the observation period and were characterized by 
reduced insulin sensitivity, the absence of a significant meal-reduced 
suppression of ghrelin, as well as a flattened meal-induced increase of PYY and 
GLP-1.  
The results of our study showed no amelioration in fasting glucose in animals 
submitted to both SG or GB (which incorporates duodenal exclusion) and 
contrast with previous findings regarding the effects of GB, duodenal exclusion 
or SG on fasting glucose in GK rats (Donglei et al., 2012; Liu et al., 2011; 
Pacheco et al., 2007; Rubino and Marescaux, 2004). Nevertheless, other 
studies could not find significant differences in fasting glucose in GK rats 
submitted to GJB or other forms of duodenal exclusion in comparison to 
controls, which is consistent with our results (de Luis et al., 2012; Kindel et al., 
2009). However, our study could show amelioration in overall glycemic control 
                                                             
8
 Adapted from published articles or manuscripts submitted for publication.  
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demonstrated by improved glycated hemoglobin levels in GK rats submitted to 
SG or GB, not assessed in any of the previous studies. 
Analogies regarding beta-cell dysfunction in human T2D and GK rats include 
reduction in beta-cell mass, alterations in microenvironment in islets, and 
multiple functional deficits (Portha et al., 2009; Seiça et al., 2003b). As 
expected, GK rats in the present study showed an impaired metabolic control in 
comparison to Wistar rats, with significantly worse levels of HbA1c at the 
beginning and at the end of the observation period. However, rats submitted to 
SG or GB improved their HbA1c levels significantly, although meal induced 
insulin secretion (expressed as AUC) did not change (GKSG) or even 
diminished (GKGB). A similar reduction in insulin secretion has been observed 
after GJB (Weng et al., 2013). Fasting insulin levels do not seem to be affected 
by surgery (Donglei et al., 2012). Nevertheless, other studies reported 
conflicting results after a prolonged follow-up (Speck et al., 2011; Trung et al., 
2013). Possibly, the improved insulin sensitivity observed in our study might 
have contributed to amelioration of glucose metabolism. Furthermore, a 
decrease in insulin resistance and enhanced glycemic control has been also 
described after dietary restriction in GK rats, together with modulation of 
systemic and muscle oxidative stress markers (Rodrigues et al., 2011).    
Glucagon secreted from pancreatic α-cells acts as a counterregulatory hormone 
for insulin and promotes elevation of blood glucose by hepatic glycogenolysis 
and gluconeogenesis (Jiang and Zhang, 2003). Consequently, a role in the 
pathophysiology of T2D has been proposed (Quesada et al., 2008; Unger and 
Orci, 1975; Unger, 1985). Besides secretion in response to low plasma glucose 
levels, plasma concentration of glucagon is modulated by insulin at an intra-islet 
level inhibiting secretion at high insulin levels (Bansal and Wang, 2008). 
Interestingly, the results of our study showed stable levels of plasma glucagon 
during the postprandial period with a slight rise at 30 minutes in WIC, GKC and 
GKSS, following a significant increase in plasma insulin at 20 minutes in GK 
rats (at 30 minutes in WIC). Apparently, no inhibition of glucagon secretion did 
occur. In rats submitted to SG or GB, a significant increase in plasma glucagon 
followed a rise in plasma insulin, but with a descending glucagon-insulin ratio 
that recovered at 60 minutes. Although an increased fasting plasma glucagon 
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and a delayed glucose-stimulated suppression has been described in humans 
with T2D (Knop et al., 2012), meal-induced or glucose-stimulated glucagon 
secretion increased after SG, albeit an improved glucose tolerance (Laferrère et 
al., 2008; Salehi et al., 2011). A similar postprandial rise in glucagon has been 
observed in humans with type 1 diabetes, not submitted to surgery, whereas 
glucagon in β-cell competent individuals remained stable (Cooperberg and 
Cryer, 2009), suggesting other stimuli for glucagon secretion besides 
hypoglycemia or decrease of insulin secretion during hypoglycemia.  
Impaired pathways regarding the inhibitory effect of hyperglycemia on glucagon 
secretion, referred to as α-cell resistance, have been identified in studies of α-
cell lines (Xu et al., 2006). Interestingly, a switch-off signal from zinc atoms, 
whether bound to insulin or not, also seems to be involved in initiating glucagon 
release from the alpha-cell, as could be shown in streptozotocin-induced 
diabetic Wistar rats (Zhou et al., 2007). The removal of somatostatin-mediated 
inhibition of glucagon secretion via pancreatic delta-cells by sympathetic 
activation may further contribute to inadequate glucagon secretion (Hauge-
Evans et al., 2010). As suggested by present data, the multifactorial regulation 
of glucagon secretion and its importance regarding glucose metabolism need to 
be further elucidated.  
The results of our study refer to meal-induced plasma levels of insulin and 
glucagon regarding a specific type of liquid diet and results may vary with 
carbohydrate content (Gutniak et al., 1986). Analysis of glucose metabolism 
was carried out rather early after surgery and might not reflect changes after a 
more prolonged follow-up. As such, data should be interpreted with caution 
regarding the long-term impact of bariatric and metabolic surgical procedures 
on plasma glucagon. However, our data questions the role of 
hyperglucagonemia in glucose intolerance in a lean animal model of type 2 
diabetes and suggests that the role of glucagon in glucose metabolism after 
bariatric and metabolic surgery deserves further studies. 
In obese humans, reported effects of bariatric surgery on fasting ghrelin are 
contradictory indicating either a reduction after surgery (Cummings et al., 2002; 
Frühbeck et al., 2004b), or unchanged fasting plasma ghrelin levels in weight-
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stable patients. In patients experiencing active weight loss after gastric bypass 
surgery, even an increase in fasting ghrelin was observed (Borg et al., 2006; 
Faraj et al., 2003; Holdstock et al., 2003).  
In an animal model, GK rats submitted to either SG alone or SG with duodenal-
jejunal bypass (SGDJB) showed significantly reduced fasting ghrelin in 
comparison to controls, two and 16 weeks after surgery (Sun et al., 2012). 
Similar results were reported by Trung and coworkers regarding fasting levels of 
des-acyl ghrelin in GK rats and diet-induced obese Wistar rats after sleeve 
gastrectomy (Trung et al., 2013). No meal-induced measurements were made 
in both studies.  
In contrast, our study did not show any differences in fasting ghrelin between 
Wistar and GK rats, independent of allocated treatment. Also in a non-diabetic 
animal model on a high-fat diet, fasting ghrelin levels were similar after GB in 
comparison to pair-fed controls. However, a significant meal-induced 
suppression was observed in rats submitted to GB (Shin et al., 2010). Our data 
showed a significant meal-induced decrease in plasma ghrelin in Wistar rats, 
not observed in control or sham operated GK rats. Interestingly, a similar 
postprandial suppression of plasma ghrelin was present in GK rats submitted to 
SG or GB. Apparently, the dynamic meal-induced response in plasma ghrelin is 
the distinguishing feature of operated GK rats in comparison to GK controls. As 
this dynamic response was also present in non-diabetic Wistar rats, our data 
might indicate that SG and GB restored an apparent defect in meal-induced 
suppression of plasma ghrelin in GK rats. A recent clinical study showed an 
analogous association between postprandial ghrelin suppression and 
postoperative weight loss, insulin sensitivity, and peak GLP-1 secretion in 
obese diabetic patients submitted to gastric bypass (Samat et al., 2013). Hence, 
fasting plasma ghrelin levels seem to represent a subordinate factor regarding 
the effects of surgery.   
Ileal interposition in a rodent model of T2D with mild obesity (UCD-T2DM rats) 
showed ameliorated glucose tolerance and reduced fasting glucose levels, eight 
months after surgery. Stimulated PYY levels by an oral lipid load were 
significantly higher than in sham operated animals (Cummings et al., 2010). In 
another study, SG and SGDJB in GK rats had similar effects on fasting and 
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stimulated PYY levels, two and 16 weeks after surgery. A significant increase 
was observed in comparison to sham operated animals and control group at all 
time points (Sun et al., 2012). In contrast, our study showed no increase in 
fasting PYY after either SG or GB. Meal-induced PYY levels were significantly 
increased in GK rats submitted to GB or SG in comparison to sham-operated 
animals or controls. However, postprandial peak PYY levels after GB were 
significantly higher than after SG.  
In a clinical study, including 58 normal-weight, overweight, or mildly obese 
diabetic patients submitted to SG with an additional intestinal procedure (ileal 
interposition or ileal interposition with diversion of the duodenum), improved 
glycemic control after surgery was observed in over 90% of cases. Hormonal 
evaluation before and after a mixed meal showed a significant increase in 
plasma PYY at all time points (fasting, 30 minutes, 60 minutes, 120 minutes). 
Also fasting and meal-stimulated GLP-1 levels increased significantly after both 
operations (DePaula et al., 2009). Nonetheless, the specific contribution of 
either component of the surgical procedure (SG or ileal interposition) regarding 
changes in gut hormone profiles and glycemic control could not be assessed.  
In our lean animal model of T2D, SG alone would increment meal-induced 
plasma levels of GLP-1 without duodenal diversion or ileal interposition. Similar 
results were obtained after GB. In diabetic rodents with mild obesity (UCD-
T2DM rats), ileal interposition without SG would increment meal-induced 
response in plasma GLP-1 (Cummings et al., 2010). Interestingly, glucose-
stimulated GLP-1 levels in GK rats were significantly higher after SG with 
duodenal-jejunal bypass than after SG alone, but no measurements after a 
mixed meal were obtained. Moreover, overall glycemic control was not 
enhanced by SGDJB in comparison to SG alone (Sun et al., 2012). 
In non-diabetic obese patients no significant differences between SG and GB 
regarding the postoperative meal-induced increment in PYY and GLP-1 could 
be found (Peterli et al., 2012). To our knowledge, no similar studies have been 
carried out in non-severely or morbidly obese diabetic patients. A recent study 
in obese diabetic patients compared the effects of BPD with a long alimentary 
limb and SG on glycemic control and gut hormones. No significant differences 
regarding diabetes control and glucose-stimulated increment in GLP-1 and PYY 
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were found between groups (Tsoli et al., 2013). However, treatment arms were 
not randomized and indication for surgical intervention was based on BMI (all 
patients with BMI > 50 kg/m2 were assigned to open BPD).  
As could be shown in the present study, and somewhat intriguingly, SG and GB 
showed similar meal-induced responses in gut hormones like PYY and GLP-1 
secreted by L-cells present in the distal ileum. Hence, mechanisms other than 
direct contact of food with the intestinal mucosa are probably involved in the 
secretion of gut hormones, yet to be explored. However, the importance of intra-
duodenal fat hydrolysis on GLP-1 secretion was documented in healthy 
volunteers that received an intra-duodenal fat infusion with or without a 
irreversible inhibitor of gastro-intestinal lipases (orlistat). Moreover, the effect of 
intra-duodenal fat hydrolysis was more pronounced after the infusion of long-
chain fatty acids and apparently mediated by cholecystokinin as the selective 
blockade of the CCK-1 receptor would abolish the effect of fat hydrolysis on 
GLP-1 secretion (Beglinger et al., 2010).  
In general, gastrointestinal surgical procedures like SG or GB improve diabetes 
control and represent an accepted therapeutic option, at least in obese patients 
(American Diabetes Association, 2014; Dixon et al., 2011). They have a well-
documented effect on the secretion of gut hormones that, by themselves, are 
believed to exert a favorable influence on glucose homeostasis. In diabetic 
patients, the subcutaneous administration of GLP-1 analogues improves 
glycemic control, supposedly through stimulation of glucose-dependent insulin 
secretion and suppression of glucagon secretion (Shyangdan et al., 2010). 
Furthermore, symptomatic hyperinsulinism after GB was controlled by 
administration of Exendin 9-39, a GLP-1 receptor antagonist, indicating a 
significant role for the insulinotropic action of GLP-1 after bariatric surgery 
(Salehi et al., 2014, 2011). Moreover, the favorable effects of IT on glucose 
tolerance after oral glucose administration in diet-induced obese Long-Evans 
rats was reversible after administration of Exendin 9-39, supporting evidence of 
direct effects of GLP-1 on glucose homeostasis (Gaitonde et al., 2012).  
As shown in the present study, meal-induced secretion of GLP-1 is enhanced 
after surgery in GK rats and becomes similar to secretion in non-diabetic Wistar 
rats. However, concerning pancreatic hormone secretion, improvement of 
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glucose homeostasis was not associated with an enhanced meal-induced 
insulin secretion. Furthermore, a study on the effect of SG on weight loss and 
glucose tolerance in GLP-1 receptor-deficient mice and wild-type controls 
showed that post-procedural improvement was similar in both groups (Wilson-
Pérez et al., 2013). Consequently, other factors than direct stimulation of insulin 
secretion through surgically enhanced GLP-1 plasma levels are possibly 
involved in ameliorated glycemic control (Vidal and Jiménez, 2013). However, 
reduced meal-stimulated increase in GLP-1 secretion was associated with failed 
weight loss after GB (de Hollanda et al., 2014). Thus, GLP-1 secretion seems to 
be associated rather indirectly with improvement of glucose tolerance after 
metabolic surgery and not through direct stimulation of insulin secretion. 
A recent and intriguing approach to further clarify the improvement of glucose 
homeostasis after GB refers to reprogramming of intestinal glucose metabolism, 
including up-regulation of glucose transporter-1 and enhanced basolateral 
glucose uptake. Apparently, increased metabolic needs of the intestine and 
exposure of the Roux limb to undigested nutrients render the gut a major tissue 
for glucose disposal (Saeidi et al., 2013). Furthermore, modulation of 
inflammatory responses through gut microbiota may contribute to reduced 
insulin sensitivity in diabetic subjects and probiotics are under investigation 
concerning their potential to change the course of disease (Gomes et al., 2014; 
Tilg and Moschen, 2014). However, the true contribution of these new concepts 
to the understanding of the pathophysiology of T2D and diabetes remission 
after surgery remains to be elucidated and was not targeted by our research 
plan. 
The results of our experimental study refer to postprandial gut hormone profiles 
in anesthetized rodents and may not reflect entirely normal physiology. As many 
drugs used for induction or maintenance of anesthesia, ketamine and 
chlorpromazine used in the present study produce anticholinergic side effects. It 
has already been shown that acetylcholine enhances ghrelin secretion in the 
isolated rat stomach and in humans (Broglio et al., 2004b; Shrestha et al., 2009) 
and its inhibition might alter plasma ghrelin levels. However, as all animals in 
the present study were submitted to the same anesthetic protocol, no influence 
on observed differences between groups must be assumed. 
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Our clinical study showed that obese patients with impaired fasting glucose or 
T2D improved their metabolic control after SG and achieved a sustained weight 
loss up to 24 months of follow-up. High preoperative plasma insulin levels 
decreased significantly as early as 3 months after surgery, without any 
significant further change during follow-up. In parallel, insulin resistance 
improved to normal or near-normal values during the first 3 months, dropping 
further until the end of the first year. Despite enhanced glycemic control, beta-
cell function declined 1 year after surgery and stabilized afterwards. 
Patients with a prolonged history of IFG or T2D eventually develop beta-cell 
insufficiency characteristic of full-blown disease. However, as shown in the 
present study, before surgery most patients have very high insulin levels 
associated with insulin resistance. No pancreatic insufficiency is present and 
insulin secretion is high, although not high enough to overcome insulin 
resistance to maintain blood sugar levels in the normal range. In his original 
Banting lecture, Reaven conceived the term “syndrome X” for a cluster of 
cardiovascular risk factors linked to insulin resistance (Reaven, 1988). 
Apparently, low insulin sensitivity or insulin resistance could antecede 
impairment of glucose tolerance (Martin et al., 1992), as well as cardiovascular 
diseases or even cancer by many years (Facchini et al., 2001). More recently, 
the pathophysiology of insulin resistance has been associated with 
cardiometabolic and cardiovascular disease through mitochondrial dysfunction 
and formation of reactive oxygen species (Kim et al., 2008). In turn, reactive 
oxygen species emission and oxidative damage to key signaling mediators from 
mitochondrial dysfunction and nutrient overload are related to insulin signaling 
and the development of NAFLD (Besse-Patin and Estall, 2014).  
In our obese patients with T2D or IFG, insulin resistance returned to normal or 
near normal after 3 months, and glycemic control was restored. A pronounced 
decrease in insulin resistance up to 60 days after SG in patients with T2D was 
also observed by Rizzello and coworkers (Rizzello et al., 2010), although beta-
cell function and long-term results had not been studied. They hypothesized 
that restoration of insulin sensitivity was due to early hormonal modifications in 
the gastro-intestinal tract itself, involving GLP-1, ghrelin and PYY. For GLP-1, a 
direct effect of endovenous administration on post-prandial glycemia has been 
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shown. However, this effect could have been due to delayed gastric emptying, 
increased first-phase insulin secretion and suppression of hepatic glucose 
output (Juris J Meier et al., 2003). Insulin resistance is associated with 
triglyceride accumulation in muscle (Perseghin et al., 1999) and liver 
(Utzschneider and Kahn, 2006). Furthermore, the release of non-esterified fatty 
acids, glycerol, hormones, and proinflammatory cytokines from adipose tissue 
adds to reduced insulin sensitivity (Kahn et al., 2006). Regular aerobic exercise 
and a moderately energy restricted diet in obese individuals ameliorate NAFLD 
and insulin resistance (Bhat et al., 2012). Mobilization of triglyceride 
accumulation in muscle and liver during weight loss after surgery might 
contribute to improvement of insulin resistance. An analogous observation was 
made in insulin resistant obese patients with T2D submitted to a moderately 
hypocaloric very-low-fat diet that improved hepatic glucose metabolism with 
normalization of hepatic insulin resistance and reduction of intrahepatic lipid 
content assessed by magnetic resonance spectroscopy (Petersen et al., 2005).   
Our study showed a significant improvement of insulin resistance after 
surgically induced weight loss, followed by reduced insulin secretion. Operated 
patients experienced a decline in beta-cell function that occurred at a later stage 
of postoperative recovery and is preceded by improvement of glycemic control 
and insulin resistance. Insulin resistance and hyperinsulinemia have little 
influence on beta-cell dysfunction (Mari et al., 2011), and the majority of 
patients is characterized by a compensatory augmented preoperative beta-cell 
function (Prentki and Nolan, 2006). However, a small number of patients did 
actually present with a deteriorated beta-cell function with rather low insulin 
levels and did not obtain full remission after surgery, suggesting a partially 
irreversible decrease in beta-cell mass, possibly due to increased apoptosis 
(Butler et al., 2003) and linked glucolipotoxicity (Prentki et al., 2002), as well as 
inflammatory mechanisms (Akash et al., 2013). Two of these patients did show 
a normal insulin resistance and the third patient revealed additionally an 
increased insulin resistance. All three patients ameliorated glycemic control 
after surgery associated with a decrease in insulin resistance and an 
improvement in beta-cell function, but only one of these patients achieved 
normoglycemia. Similar observations have been made after GB in obese 
patients with T2D; beta-cell glucose sensitivity did not return to normal, one 
P a g e  | 98 
 
year after surgery (Nannipieri et al., 2011). Thus, prognosis of remission of T2D 
after bariatric surgery is probably linked to preoperative beta-cell function.  
Several studies associated favorable outcome regarding diabetes remission 
after bariatric or metabolic surgery to clinical and laboratorial parameters like 
higher BMI, lower age, shorter duration of diabetes, lower levels of HbA1c or 
FPG, and no requirement for insulin (Casella et al., 2011; Hayes et al., 2011; 
Huang et al., 2011). However, these factors probably reflect rather indirectly the 
relative significance of insulin resistance and deterioration of beta-cell function 
for impairment of glucose homeostasis in individual patients. Recent data 
support the prognostic value of pre-operative C-peptide assessment for 
predicting successful outcome after surgery (Lee et al., 2013, 2012). 
Furthermore, even patients with clinical remission of T2D may not have entirely 
recovered beta-cell function after surgery (Dutia et al., 2014).  
Relative improvement of beta-cell function in patients with an impaired 
preoperative beta-cell function is possibly due to an increased postoperative 
meal-induced secretion of gastrointestinal hormones like GLP-1 which has 
shown to exert a stimulating effect on insulin secretion (Jørgensen et al., 2013) 
and, hypothetically, on beta-cell survival. Further studies in diabetic patients 
with beta-cell dysfunction could additionally clarify the hypothesis that success 
of surgery in this subgroup of patients depends on surgical technique. It has 
already been shown that BPD or BPD-DS are particularly efficient in obese 
patients with T2D (Buchwald et al., 2009; Marinari et al., 2006), whereas II-SG 
could apparently improve diabetic control in non-obese patients (De Paula et 
al., 2010). Stimulation of L-cells in the distal small intestine through early 
contact with food and subsequent secretion of gastrointestinal hormones like 
GLP-1 and PYY is probably highest with these surgical techniques and could be 
responsible for improved glycemic control (Strader et al., 2005). However, the 
specific effect on beta-cell function in the subgroup of patients with beta-cell 
insufficiency remains to be further elucidated.  
Limitations to our clinical study include sample size and the presence of drop-
outs. Selection bias regarding surgical technique was avoided since all bariatric 
patients with T2D or IGF treated by the author during the above-mentioned 
period were included in the study. Statistical methods were adequate to validate 
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observed differences in studied parameters. However, the study of patient 
cohorts from other centers would further consolidate our observations. Benefits 
from a longer follow-up period include the possibility of identifying specific 
patient groups whose results hold up over time. Our study favors the prognostic 
value of preoperative assessment of beta-cell function and insulin resistance 
through mathematical models, possibly facilitating the stratification of prognosis 
after surgery. Consequently, it would be interesting to study patients submitted 
to GB or BPD/BPD-DS to improve our knowledge regarding the role of insulin 
resistance and beta-cell function in the context of other surgical techniques and 
eventually permit to tailor the procedure to an individual patient.  
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CONCLUSION 
Both SG and GB improved overall glycemic control and insulin sensitivity in GK 
rats, a lean animal model of T2D. Regarding secretion of pancreatic hormones, 
no significant differences in total meal-induced insulin secretion were observed 
between Wistar rats and GK rats in all groups. GK rats showed similar glucagon 
levels in comparison to non-diabetic Wistar rats, without any variation in 
response to a mixed meal. However, GK rats submitted to SG and GB showed 
a significant rise in glucagon, 30 minutes after a mixed meal, as well as an 
increased glucagon-insulin ratio at 60 minutes, albeit a significant amelioration 
of overall glycemic control. Apparently, an augmented post-procedural glucagon 
secretion after surgery does not contribute to an impaired glucose tolerance. In 
face of our results, the role of glucagon on glycemic control after bariatric 
surgery deserves further investigation. 
Sham operated or control group GK rats showed a distinct postprandial gut 
hormone profile if compared to non-diabetic Wistar rats. Meal-induced gut 
hormone profiles in GK rats submitted to either SG or GB showed significant 
post-operative modifications and were similar to Wistar rats. Gastrointestinal 
surgical procedures modulated both suppressed postprandial ghrelin secretion 
and flattened meal-induced response of PYY and GLP-1, characteristic for lean 
diabetic GK rats. Duodenal exclusion alone does not seem to play a significant 
role in post-surgical amelioration of T2D and restoration of gut hormone profile. 
Mechanisms other than the direct contact of food with the intestinal mucosa 
should be taken into account to explain the effect of surgery on postprandial gut 
hormone secretion.   
The results of our clinical study suggest that in most obese patients, T2D is 
preceded by an enhanced beta-cell function in response to an increased insulin 
resistance. Later, as disease progresses, augmented beta-cell function cannot 
compensate for insulin resistance anymore and IFG or overt T2D arise. At this 
stage, the disease remains reversible by reduction of insulin resistance through 
bariatric surgical techniques like SG, possibly due to reduction of intracellular 
lipid load and improvement of mitochondrial dysfunction. Apparently, prognosis 
concerning diabetes remission is dubious in patients with impaired preoperative 
beta-cell function, but other surgical approaches, namely BPD-DS or IT, may 
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yield favorable results in this subgroup of patients that, however, still warrant 
confirmation.  
Taken together, the results of our study demonstrate that important changes in 
gut hormone profiles occur together with amelioration of glucose homeostasis 
after bariatric and metabolic surgical procedures, even in the absence of 
significant obesity, whereas the modulation of pancreatic hormone secretion 
seems to play a subordinate role. Sleeve gastrectomy, a technique without 
duodenal exclusion, is effective in a lean animal model and in obese humans 
with T2D. Preoperative beta-cell function and insulin resistance are likely to 
represent important prognostic factors for outcome after surgery that should be 
assessed in all patients with T2D or IFG proposed for metabolic surgery to 
permit stratification and evaluation of surgical efficacy.  
In the context of our data, the mechanisms of modulation of pathophysiological 
pathways for insulin resistance through gastrointestinal surgery deserve further 
investigation and shall represent an interesting field for future research. 
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